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ADVANCED GLYCATION ENDPRODUCTS 
What are advanced glycation endproducts (AGE), and how are they formed? Basically, 
AGE are the end products of a complex and diverse process of irreversible binding of 
sugars to other molecules in the body. The binding of sugar is called glycation and 
especially a"ects certain amino acids (like lysine).
 Several pathways can lead to the formation of AGE (!gure 1). The classical pathway 
is the Maillard reaction, called after the food chemist M. C. Maillard who !rst described 
the process in 1912. The !rst step is non-enzymatic glycation by the covalent binding 
of the carbonyl group of reducing sugars to free amino groups of a protein, forming an 
instable Schi" base. Secondly, a more stable intermediate Amadori product is formed 
by re-arrangement of the Schi" base by move of the hydrogen atom, leaving a ketone. 
One of the most well-known Amadori products is HbA1c, glycated haemoglobin, 
which is widely used to monitor diabetes regulation. Only a small part of the relatively 
stable Amadori products undergoes further oxidative reactions resulting in irreversible 
AGE. The best known representatives are pentosidine, carboxymethyllysine (CML) and 
pyrraline. The formation of AGE by this Maillard reaction is slow and concentration 
dependent and accelerates under conditions of hyperglycemia. Therefore, formation of 
AGE by the Maillard reaction is increased in diabetes mellitus.1,2 
 Besides this slow pathway of AGE formation it has now been recognised that, especially 
intracellularly, rapid formation of AGE may occur via reactive carbonyl compounds like 
glyoxal, methylglyoxal and 3-deoxyglucosone. Methylglyoxal leads to formation of AGE 
such as carboxyethyllysine (CEL) and methylglyoxal-derived hydroxyi midazolone (MG-
H1), while glyoxal and 3-DG may result in formation of CML and pyrraline. The formation 
of reactive carbonyl compounds is mainly the result of oxidative stress.3,4 
 Peroxidation of polyunsaturated fatty acids to lipid peroxides may also modify 
proteins and result in so-called advanced lipoxidation endproducts (ALE): the lipid 
peroxides are then transformed to reactive carbonyl compounds which then again 
may react with amino acid residues.5 This may also occur on nucleic acids. Thus, AGE 
formation may result from oxidative/carbonyl stress besides hyperglycemia.
 In#ammation may contribute to AGE formation. Activation of neutrophils, monocytes 
and macrophage result in release of myeloperoxidase and NADPH oxidase enzymes. 
These enzymes may react with amino acids to form AGE.6 
 Another cause of AGE formation or accumulation is decreased renal clearance of 
AGE precursors in renal insu$ciency.4 On top of this, renal insu$ciency causes oxidative 
stress causing AGE formation.4,7,8
 Finally, cigarette smoke and several food products are a source of AGE9,10,11. Some 
foods are extremely rich in AGE like for example crème brulée. Fortunately, only 
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10% of ingested AGE are indeed absorbed by the intestine.10 An interesting detail: 
caramellisation of sugar is fact is nothing less than degrading sugar into AGE by heating. 
Figure 1: Schematic view of the complex Maillard reaction and other pathways leading to the 
formation of AGE.
Accumulation of AGE in long lived tissues: a metabolic memory
In the process of AGE formation molecules are irreversibly changed and deformed. In 
tissues with a short life time, the deformed molecule is quickly degraded, limiting any 
negative e"ects. However, in long lived tissues AGE continue to accumulate.12 Collagen 
in the dermis and vascular wall has a lifespan of 15-20 years while collagen in cartilage 
has an even longer lifetime and collagen in the crystalline lens of the eye even endures 
a lifetime. The deformation of long lived tissues by AGE is regarded as a normal process 
with ageing.13 An increase of AGE accumulation is however seen in several diseases: 
diabetes mellitus (as a result of hyperglycemia),14 renal failure (as a result of decreased 
excretion of AGE precursors and increased oxidative stress)4,8 and chronic in#ammatory 
diseases like rheumatoid arthritis and systemic lupus (as a result of activation of 
neutrophils, monocytes and macrophages).15-17 The accelerated AGE accumulation 
seen in those conditions contributes to long term complications and mortality.18-21 AGE 
accumulation in long lived tissues, therefore, seems to re#ect a metabolic memory of 




The negative consequences of AGE accumulation
There are several reasons why AGE accumulation has deleterious e"ects. First of all, 
AGE formation changes the basic (tertiary) structure of the a"ected protein, lipid or 
DNA leading to dysfunction. Also, AGE can form crosslinks between molecules which 
interferes with normal function.22,23 Crosslinking of AGE of vascular collagen/elastin 
contributes to arterial sti"ness and crosslinking of skin collagen results in wrinkles.24 
Sometimes, AGE interfere with physiological degradation of the molecule. Adherence of 
AGE to cellular binding sites (especially mitochondrial) alters intracellular signalling and 
can ultimately lead to intracellular oxidative stress which causes a vicious cycle.25 Finally, 
AGE can activate cell membrane receptors. The most notoriously known receptor to 
be activated by AGE is called the receptor for AGE (RAGE). This receptor is present on 
endothelial cells and several other cell types and leads to activation of several oxidative 
and in#ammatory pathways.26
Figure 2: The mechanisms of damage by AGE. Crosslinking of proteins, intracellular glycation 
and activation of the receptor for advanced glycation end products (RAGE) all contribute to the 
deleterious e"ects of AGE accumulation. 
Atherosclerosis and AGE
Increasing evidence shows that AGE play a major role in atherosclerotic disease, 
irrespective of the presence of diabetes mellitus and renal insu$ciency. 
 How AGE can induce atherosclerosis is also explained by several mechanisms 
shown by in vitro studies. AGE interact with their receptors on endothelial cells, 
smooth muscle cells and macrophages. This induces focal adhesion molecules (VCAM-
1), cytokine expression which may promote formation of atherosclerotic plaques.27 
Crosslinking of vascular collagen promotes vascular sti"ness, hypertension and vessel 
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leakage.24,28 AGE deposition may also attract monocytes to transmigrate into the vessel 
wall and subsequently release pro-atherogenic mediators.29 Nitric oxide plays an 
important protective role in the vascular wall. AGE can (directly or via RAGE mediated 
mechanisms) reduce the release of nitric oxide or captivate nitric oxide.30 AGE also trap 
LDL cholesterol in the subendothelium.31 Glycoxidation of LDL particles induces loss of 
their a$nity to bind to the LDL receptor, impairing hepatic clearance.32 Also, uptake of 
LDL by scavenging receptors on macrophages and smooth muscle cells is promoted.32 
This all leads to increased LDL retention in the vessel wall and an increase in foam cells. 
Transformation to foam cells is also enhanced by RAGE receptor stimulation. Also, 
the cardioprotective function of HDL may be impaired by glycoxydation.33,34 All these 
factors contribute to an accelerated progression of atherosclerosis as a result of AGE 
accumulation in the arterial vessel wall. 
 Besides these in vitro !ndings, evidence for a role of AGE in atherosclerosis also comes 
from animal studies. In rabbits, intravenous infusion of AGE and local application of AGE 
resulted in intimal thickening.35 Conversely, a study in mice showed that treatment against 
AGE by either the soluble receptor for AGE (sRAGE), an AGE inhibitor (aminoguanidine) 
or AGE cross link breaker (ALT-711) resulted in an attenuation of atherosclerosis. A 
decrease in plaque area of 30-40% was observed.36,37 Another experimental animal 
study showed that knocking out the receptor for AGE (RAGE) protected these animals 
against ischemic reperfusion injury.38 Knocking out the receptor for AGE in diabetic 
apoE(-/-) mice reduced atherosclerotic plaque area to levels of non-diabetic mice. 
/-0.4%) to levels not signi!cantly di"erent from control apoE(-/-) mice.39 Furthermore, a 
low AGE diet compared to high AGE diet resulted in a 50% fall in atherosclerotic burden 
in Apolipoprotein-E de!cient mice.40 NO-dependent vasorelaxation is signi!cantly 
reduced by exposure to high glucose and the AGE methylglyoxal. However, glyoxalase-I 
transgenic animals (who, therefore, have a high glyoxalase-1 level that protects against 
methylglyoxal) have a normal NO-dependant vasorelaxation. This proves that AGE 
impair NO-dependent vasorelaxation and, therefore, interfere with normal endothelial 
function.41  
 Human data primarily show associations between AGE and atherosclerosis and 
vascular function. Serum levels of the AGE carboxymethyl-lysine were associated with 
increased aortic pulse wave velocity in adults.42 Also, skin auto#uorescence as a marker 
for AGE accumulation, is associated with arterial sti"ness in patients with end-stage 
renal disease and in diabetes.43,44 Patients with carotid disease have an elevated serum 
level of AGE. A positive association between intima media thickness (IMT) and serum 
levels of AGE was found in a population with renal insu$ciency starting dialysis.45 Also, 
AGE have been localized in atherosclerotic lesions, fatty streaks, lipid containing smooth 
muscle cells and macrophages.46 This phenomenon was not only seen in patients with 
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diabetes, but also in normoglycemic patients.47,48 Baumann et al. showed that the 
AGE N-epsilon-carboxymethyllysine (CML) is present in the subendothelial space of 
atherosclerotic human carotid artery material of normoglycemic subjects with a mean 
age of 50 year.49 A clear correlation was found between tissue AGE concentration and 
severity of atherosclerotic lesions. 
HOW TO MEASURE AGE ACCUMULATION?
Serum AGE levels
AGE are di$cult to measure: it is not a single entity, but a group of structurally very 
diverse glycation end products. Di"erent assays have been developed to assess serum 
levels of AGE with a known structure. Especially tandem mass spectrometry dependent 
methods, usually preceded by HPLC (high performance liquid chromatography) or 
UPLC, are now considered as the gold standard. Besides technical di$culties, the major 
problem is that serum levels of AGE simply do not necessarily re#ect accumulation of 
AGE in long-lived tissue.50,51 Also, assessment of a speci!c AGE does not necessarily 
re#ect the whole group of AGE. 
Tissue AGE accumulation
Tissue AGE accumulation can be assessed in skin biopsies, but the process is invasive 
and time consuming. Genuth et al showed that tissue AGE levels in skin biopsies 
predicted future progression of diabetic complications.19 There is the pitfall of focusing 
on one speci!c AGE instead of the whole group. A method that gives a broader view 
of AGE accumulation is the protein cross-linking index in collagen rich biopsy material, 
but it has a low speci!city. A di"erent method, !rst introduced by Monnier et al in the 
1980s, uses the #uorescent properties of some AGE and measures collagen linked 
#uorescence which gives an indirect quantitative measure of tissue AGE accumulation.52 
Unfortunately, having to take skin biopsies in order to measure tissue AGE accumulation 
is a practical barrier for routine use in medical practice.
 
The AGE Reader
A noninvasive method to estimate AGE accumulation in tissue became available in 
2006: the AGE reader (Diagnoptics Technologies, Groningen, The Netherlands).53 This 
technique uses the auto#uorescent properties of some AGE and assesses accumulation 
of AGE in tissue through illumination of the skin (!gure 3). The AGE Reader illuminates a 
skin surface of 4 cm2 on the volar site of the underarm guarded against surrounding light. 
The excitation light source has a peak excitation of 370 nm (with a range of 350-420 nm). 
General introduction and aims of the thesis 
1
19
This wavelength is in the UVA spectrum. Emission light in the wavelength range of 420-
600 nm (#uorescence) and excitation light that is re#ected by the skin with a wavelength 
range of 300-420 nm is measured with a spectrometer. Skin auto#uorescence (SAF) is 
the ratio between the emission light (#uorescence) and the re#ected excitation light. 
This ratio is multiplied by 100x and expressed as arbitrary units (AU). SAF has previously 
been validated by simultaneous measurements of SAF and contents of speci!c AGE 
assessments in skin biopsies. Although the #uorescent characteristics used by the AGE 
reader are not speci!c for #uorescent AGE, multiple validation studies have shown 
convincingly and consistently that SAF has a strong correlation with speci!c AGE content 
in skin biopsies. The correlation between skin AF with the #uorescent AGE pentosidine 
is very high: r=0.87. Surprisingly, not only #uorescent AGE (pentosidine) but also non 
#uorescent AGE (N-carboxymethyl-lysine (CML) and N-carboxyethyl-lysine (CEL)) in the 
skin biopsies showed great correlation with SAF. Skin AGE content explained the major 
part of the variance (up to 76%) in the SAF signal in a pooled analysis of three validation 
studies.53,54 Therefore one can conclude that skin auto#uorescence can be used as an 
indirect, noninvasive estimate of AGE accumulation in tissue.53
Figure 3: The AGE Reader illuminates a skin surface of 4 cm2 on the volar site of the underarm 
guarded against surrounding light. The excitation light source has a peak excitation of 370 nm 
(range of 350-420nm). Emission light in the wavelength range of 420-600 nm (#uorescence) and 
excitation light re#ected by the skin (wavelength 300-420 nm) is measured with a spectrometer. 
SAF is the ratio between the emission light (#uorescence) and the re#ected excitation light.
A device comparable to the AGE reader, the SCOUT (developed by the US-based 
company Veralight Inc) has also been developed.55
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Furthermore, a Fluototron device has been used in ophthalmology for measuring 
corneal or lens auto#uorescence, which has been related to local AGE levels.56
AIMS OF THIS THESIS
This thesis has two major aims. After depicting the background of AGE and SAF, the 
!rst aim is to explore possible factors that interfere with the measurement of SAF. The 
second aim is, to investigate the relation between SAF and atherosclerosis in di"erent 
vascular beds. 
 Part I presents an overview of the existing knowledge on advanced glycation end 
products (AGE), with chapter 2 focussing on their role in renal failure. This background 
information forms the starting point of this thesis. 
 Part II addresses di"erent factors that may in#uence the measurement of SAF. In 
previous studies, SAF proved to be a predictor of mortality and complications in type 
2 diabetes mellitus and renal failure. As the use of SAF is increasing, it is important to 
assess and review what factors might in#uence or disturb the measurement. Chapter 
3 explores the in#uence of short- and medium term glycemic variation on SAF. The 
e"ect of AGE rich meals, postprandial rise in glucose levels, impaired glucose tolerance 
and HbA1c on SAF is studied. Chapter 4 investigates the in#uence of several dermal 
factors that could possibly disturb SAF measurements. E"ects of several skin creams, 
hyperemia, vasoconstriction and hydration/moisture of the skin are evaluated. 
 Part III of this thesis focuses on SAF, as a measure of AGE accumulation, in patients 
with atherosclerotic disease in di"erent vascular beds. Chapter 5 evaluates SAF in a 
small cohort of patients with carotid artery stenosis compared to healthy age matched 
controls. Chapter 6 addresses SAF in patients with peripheral artery disease (PAD). We 
present a case control study of 492 patients with PAD and 164 controls, matched for 
age and presence of diabetes mellitus. Cardiovascular risk factors and comorbidity 
(coronary artery disease, cerebrovascular disease, abdominal aortic aneurysm are 
assessed. Chapter 7 addresses the relation between SAF and diabetic complications in a 
secondary care, hospital-controlled group of patients with type 2 diabetes. We analysed 
563 subjects with type 2 diabetes mellitus followed in 5 Dutch hospitals. It is a validation 
study to con!rm previous !ndings in a single center primary care setting which showed 
that SAF is markedly increased in patients with diabetes mellitus type 2 and has a graded 
relation with diabetic complications.
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The article aims to present an overview of the existing knowledge on advanced 
glycation end products (AGE). They are moieties that bind to proteins, but also lipids 
and nuclear acids. AGE are formed during glycation and oxidative stress. Accumulation 
of AGE occurs especially in diabetes and chronic renal failure and plays a major 
pathogenetic role. The deleterious e"ects of AGE result from cross linking of proteins 
and activation of the receptor for advanced glycation end products. AGE accumulation 
can be non-invasively assessed by the skin auto#uorescence reader. In diabetics, 
skin auto#uorescence predicts cardiac mortality and the occurrence of macro- and 
microvascular complications. In patients on haemodialysis, skin auto#uorescence is 
highly elevated and predicts mortality. After renal transplantation AGE accumulation is 
lower than during haemodialysis, but still remains elevated and is a strong risk factor for 
chronic renal transplant dysfunction. Some of the potential methods to intervene with 
AGE accumulation are discussed in this article.




Advanced glycation end products, also called AGE, play a major pathogenetic role 
in many age related diseases. They are also a cornerstone in the development of 
complications associated with diabetic nephropathy and chronic kidney disease (CKD). 
Here an overview is presented of the existing knowledge on AGE, focussing on their role 
in renal failure. 
What are advanced glycation end products?
Advanced glycation end products (AGE) are glycated moieties that bind to proteins, but 
also lipids and nuclear acids. AGE are formed during glycation and also during oxidative 
stress. Glycation can result from several di"erent mechanisms. Classically, advanced 
glycation end products are formed by a complex and sequential nonenzymatic reaction, 
called the “browning reaction” !rst described by Maillard in 1912. Hyperglycaemia and 
diabetes mellitus contribute to an enhanced formation of AGE by this Maillard reaction. 
During the process intermediate products, called Amadori products, are formed. A very 
well known Amadori product is the HbA1c, a glycated haemoglobin used to monitor 
diabetic regulation. AGE can also form during oxidative stress as a result of reactive 
carbonyl products.1 For example, oxidative stress as a result of a myocardial infarction 
may cause a signi!cant temporary rise in AGE (submitted data). Intake of many food 
products and smoke, containing AGE are the third source of AGE.2,3 Fortunately, only 
10% of ingested AGE are indeed absorbed by the intestine.3 
Accumulation of AGE 
The linking of AGE to a protein can occur on any protein in the body. The resulting 
alteration is irreversible and chemically stable. Therefore, the lifetime of the AGE is 
determined by the lifetime of the protein they form on. Skin collagen, lens crystallins 
and cartilage proteins are very long-lived proteins and as a result AGE accumulation on 
these proteins continues throughout lifetime.4 AGE linked to such long-lived proteins 
are therefore considered to be a long-term memory of both glycaemic stress (especially 
in diabetes) and oxidative stress. On short-lived proteins, the protein and its linked AGE 
product will be rapidly degraded to AGE peptides which are subsequently excreted by 
the kidney. The clearance of AGE modi!ed peptides is highly e"ective with clearances 
ranging from 35 to 90 percent. In renal failure however, the excretion of AGE is impaired, 
resulting in enhanced accumulation of AGE.5 
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Mechanisms of damage by AGE
Tissue damage as a result of AGE formation may be the result of several mechanisms 
(!gure 1). First of all, AGE formation leads to cross linking between proteins. This a"ects 
both the conformational structure and the function of proteins. These modi!cations of 
proteins occurs extracellularly as well as intracellularly.6,7 Secondly, AGE bind to receptors, 
especially the receptor for advanced glycation end products (RAGE). Activation of this 
receptor induces intracellular transduction mechanism and cellular activation which 
has deleterious e"ects.8,9 Many of the adverse e"ects of aging, diabetes and chronic 
renal failure can be attributed to accumulation of AGE. For example, wrinkling of the 
skin is the result of accumulation and crosslinking of AGE in collagen !bres of the skin. 
Atherosclerosis and vascular sti"ening is associated with AGE accumulation in the 
vessel wall. AGE accumulation in the basement membrane of the glomeruli causes 
albuminuria and eventually chronic renal failure. Senile cataract and arthrosis are other 
manifestations of AGE accumulation in the lens and cartilage, respectively. 
Figure 1: The mechanisms of damage by AGE. Crosslinking of proteins, intracellular glycation 
and activation of the receptor for advanced glycation end products (RAGE) all contribute to the 
deleterious e"ects of AGE accumulation. 
Methods to measure AGE accumulation
AGE can be measured by biochemical and immunochemical assays. Also, AGE levels can 
be assessed using their characteristic #uorescent properties. On excitation at 370 nm, 
some AGE have a typical #uorescence spectrum at 440 nm. Serum levels of AGE do 
not necessarily re#ect accumulation of AGE in tissue however.10 Quanti!cation of AGE 
accumulation in tissue is a more accurate measure of tissue damage and can be done by 
biopsy of tissue with subsequent determination of AGE levels. This is an invasive, complex 
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and expensive procedure. In 2004, a simple and non-invasive method of assessing AGE 
accumulation in skin using skin auto#uorescence was !rst described (!gure 2). Skin 
auto#uorescence measured by the so-called auto#uorescence reader correlates closely 
with AGE measurement by skin biopsy. Furthermore, the reproducibility of the skin 
auto#uorescence measurement is good (Altmann error rate of 5.03%). A measurement 
takes less than one minute and reports the results immediately, making it a practical 
tool in daily patient care.11 
Figure 2: The auto#uorescence reader. The forearm is positioned on the auto#uorescence 
reader. The device measures the skin auto#uorescence within one minute. The measured value 
of auto#uorescence is reported immediately on the computer screen.
Diabetic nephropathy
Diabetes is the most prevalent cause of renal failure. This is illustrated by the fact that 
haemodialysis is the result of end stage diabetic nephropathy in approximately 20% of 
cases.12 Patients with diabetes mellitus have a signi!cantly higher AGE level than the 
normal population as a result of glycaemic stress. AGE have long been known to play 
a major role in the pathogenesis of diabetic macro- and microvascular complications, 
including diabetic nephropathy. The AGE levels correlate with the severity and duration 
of diabetes. Monnier showed in a cross-sectional study with 216 type 1 diabetics that 
AGE accumulation in the skin not only correlates with the severity and the duration of 
diabetes, but also with the presence of long-term diabetic complications. This association 
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was so strong, that skin AGE levels explained 19-36% of variance in the incidence of 
diabetic complications in intensively treated diabetics and 14-51% in conventionally 
treated diabetics.13 Another large cross-sectional study on 973 well regulated type 
2 diabetics showed that skin auto#uorescence measured by the auto#uorescence 
reader is signi!cantly higher in type 2 diabetics with complications than those without 
complications.14 Skin auto#uorescence was highest in patients with both micro- and 
macrovascular complications (!gure 3). In prospective studies, AGE measurement 
by skin auto#uorescence also proved to be a strong predictor of cardiac mortality in 
diabetics.15 AGE measurement may even add information to the standard estimation 
of cardiovascular prognosis by the UKPDS risk-engine (H. Lutgers, unpublished data, 
reported at the EASD 2007). Moreover, skin auto#uorescence independently predicts the 
risk of developing microvascular complications like microalbuminuria and neuropathy. 
This has been proven in a 10 year follow-up study with 211 type 1 diabetics and recently 
in a 3 year follow-up study of the cohort of 973 type 2 diabetic patients mentioned 
earlier.16,17 
Figure 3: Mean skin auto#uorescence (AF) with 95% con!dence intervals in di"erent categories 
of complications in type 2 diabetics. The lined column represents the mean auto#uorescence of 
the control group. The mean auto#uorescence in the diabetic population is signi!cantly higher 
than in the control population. Diabetics with no complications had signi!cantly lower mean 
auto#uorescence than diabetics with complications. Auto#uorescence was highest in diabetics 
with both macro- and microvascular complications.
From: Skin auto#uorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. 
Lutgers HL, Graa" R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Diabetes Care. 2006 Dec;29(12):2654-
9.




AGE levels are grossly elevated in chronic kidney disease and haemodialysis as a result 
of decreased clearance, resulting in an increased tissue accumulation. The accumulation 
of AGE in renal failure is even greater than in diabetes. Mortality is extremely high in 
patients on haemodialysis and approximates 10% annually.18 High skin auto#uorescence 
as a measure of AGE accumulation has been proven to be a predictor of both overall 
and cardiovascular mortality in haemodialysis patients19 (!gure 4). Peritoneal dialysis 
results in glycemic stress as a result of high glucose contents of the dialysis solution. 
AGE have been shown to accumulate in the peritoneum, contributing to peritoneal 
degeneration and eventually technique failure.20 Strikingly, the use of peritoneal #uids 
low in glucose degradation products results in prolonged technique survival and (more 
importantly) also signi!cant patient survival.21 Peritoneal #uids with low to minimal 
glucose degradation products have therefore gained more widespread use in recent 
years. After renal transplantation, skin auto#uorescence slowly falls and is lower than 
in patients on haemodialysis, but still remains markedly elevated in spite of a dramatic 
reduction in plasma AGE.22 The cardiovascular morbidity and mortality also remain 
elevated after transplantation, presumably as a result of persisting AGE accumulation. 
Furthermore, high levels of skin auto#uorescence increase the risk of chronic renal 
transplant dysfunction.23
Figure 4: Kaplan-Meier estimates of survival during follow-up with regard to overall mortality 
in patients on haemodialysis in relation to skin auto#uorescence (AF) above and below mean 
values and the presence of cardiovascular disease (CVD) at baseline.
From: Skin auto#uorescence, a measure of cumulative metabolic stress and advanced glycation end products, 
predicts mortality in hemodialysis patients. Meerwaldt R, Hartog JW, Graa" R, Huisman RJ, Links TP, den 




No drugs that focus on reducing AGE formation or breakdown of crosslinks have 
yet been introduced for clinical use. Several human studies are currently in progress 
however. The AGE formation inhibitor Benfotiamine and crosslink breaker Alagebrium 
are now being tested. Soluble RAGE analogues are also under development to scavenge 
circulating AGE. Angiotensin converting enzyme (ACE) inhibitors and angiotensin II 
receptor blockers (ARB) are known to reduce macro- and microvascular complications 
of diabetes and also progression of renal failure irrespective of antihypertensive e"ects. 
Interestingly, these ACE inhibitors and ARB have been shown to reduce the formation of 
AGE.24,25 Also, ACE inhibitors appear to up regulate the soluble receptor for AGE.26
 Reducing the intake of AGE in food and smoke also is a possible target to lower 
AGE accumulation.3 A diet low in AGE is unpalatable, however. This makes clinical use 
di$cult, especially since patients with renal failure usually already have many dietary 
restrictions. Cessation of smoking, also a source of exogenous AGE, is also for other 
reasons obviously an important and longstanding goal in preventing cardiovascular 
events in both diabetes mellitus and renal failure.
 More e"ective removal in AGE precursors by choosing speci!c dialysis methods or 
dialysis membranes is still under investigation. Daily haemodialysis improves AGE levels.27 
Vitamin E coated dialysis membranes also reduces AGE in patients on haemodialysis.28 
Very high #ux polysulfone !lters reduce predialysis serum levels of AGE.29 Peritoneal 
dialysis solutions with a lower glucose content also reduce serum AGE as a result of a 
reduction of glycaemic stress.30 Recent preliminary data show that skin auto#uorescence 
is also lower in patients on low or no glucose containing dialysates. The same seems to 
hold for patients on high #ux dialysates (unpublished data). This suggests that over time 
the lower serum AGE levels may also lower tissue AGE accumulation and therefore limit 
the resulting damage. 
 Renal transplantation is a most e"ective treatment for lowering AGE in patients with 
renal failure, although AGE accumulation in tissue remains high in comparison with the 
normal population.22 
Conclusion
Advanced glycation end products accumulate in tissue during aging, diabetes and renal 
disease. AGE accumulation in the skin can be non-invasive and rapidly assessed by the 
auto#uorescence reader. AGE accumulation in tissue has many deleterious e"ects and 
contributes largely to the development of long-term complications and high mortality 
in both diabetes and chronic renal failure. High levels of skin auto#uorescence predict 
mortality and complications in diabetics and renal failure.




A.J. Smit is founder of DiagnOptics B.V., The Netherlands, manufacturer of the AGE-
Reader, which has been used as the device for performing skin auto#uorescence 
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Background: Accumulation of advanced glycation end products (AGE) is accelerated 
during glycaemic and oxidative stress and is an important predictor of complications in 
diabetes mellitus (DM). 
Study design: Here we both review and present original data on the relationship 
between skin auto#uorescence (SAF), a non-invasive measure of AGE, and short- and 
intermediate term glycaemic variations. 
Results: Acute changes in glucose levels during an oral glucose tolerance test in 56 
persons with varying degrees of glucose tolerance did not in#uence SAF. AGE rich 
meals result in a transient postprandial rise in SAF of 10% 2-4 hours later. This could not 
be attributed to meal-induced glycaemic changes and is probably caused by the AGE 
content of the meal. In type 1 DM major intermediate term improvements of glycaemic 
control as depicted by multiple HbA1c measurements were associated with lower skin 
AGE levels. In a well controlled, stable type 2 DM cohort, only a weak correlation was 
found between SAF and HbA1c. In both studies skin AGE/SAF levels predicted diabetic 
complications with an accuracy superior to that of HbA1c. SAF has also been proposed 
as a new tool in diagnosing IGT and diabetes mellitus. It proved to be more sensitive 
than either fasting glucose or HbA1c.
Conclusions: SAF is not in#uenced by short term glycaemic variations. AGE rich meals 
may however cause a transient rise postprandially. There is a weak correlation between 
SAF or skin AGE and current or time-integrated HbA1c levels. SAF has strong added 
value in risk prediction of complications of diabetes and is a promising tool for early 
detection of diabetes and IGT. 




Advanced glycation end products (AGEs) play a major pathogenetic role in many age 
related diseases.1 Especially in diabetes mellitus and renal failure, AGE accumulation 
is accelerated and causes long term complications and increased mortality.2-6 Tissue 
and cellular damage as a result of AGE results primarily from AGE forming cross links 
between proteins, and from binding to and subsequent activation of cell membrane 
pro-in#ammatory receptors including the receptor for advanced glycation end products 
(RAGE).7 
 Skin auto#uorescence (SAF) has become a validated and widely accepted non-
invasive method to assess tissue accumulation of AGE.8 Not surprisingly, SAF proved 
to be a strong and independent predictor of complications in diabetes mellitus.2 Also, 
it has prognostic value on top of the UKPDS risk score in predicting mortality in type 2 
diabetics.3,4 
 AGEs, especially the accumulation in long lived tissues like skin collagen, have 
been proposed by several groups including the UKPDS group as a carrier of long term 
metabolic memory of glycaemic and oxidative stress.9 Therefore, a correlation between 
SAF as a measure of tissue AGE and other parameters of glycaemic control might be 
expected. In this article we review and present original data on the relationship between 
glucose levels, HbA1c and SAF. 
Skin auto!uorescence and short term glycaemic variability 
We studied the e"ects of short term glucose variations during a glucose tolerance test 
on SAF in 56 persons. Inclusion criteria were the presence of one or more risk factors 
for diabetes, namely obesity or other criteria for the metabolic syndrome, physical 
inactivity or an abnormal high glucose value or HbA1c in the past. Exclusion criteria 
were known diabetes, chronic kidney disease with a serum creatinine of >120 umoll/
liter or an acute cardiovascular event in the previous 3 months. Subjects underwent 
an oral glucose tolerance test (OGGT) of 75 gram glucose dissolved in 120 ml of water. 
Glucose, HbA1c and SAF were determined at baseline. Furthermore, glucose and SAF 
were also measured two hours after ingestion of the 75 gram glucose. After the OGGT 
patients were classi!ed into normal glucose tolerance, prediabetes and frank diabetes. 
Here, a normal glucose tolerance was de!ned as a fasting glucose of <5.6 mmol/l and 
a glucose of <7.8 mmol/l at the OGTT at 2 hours. Prediabetes was de!ned as a fasting 
glucose of 5.6-6.9 mmol/l or a glucose of 7.8-11.0 mmol/l at 2 hours of the OGGT. 
Diabetes was de!ned as a fasting glucose ≥7.0 or a glucose of >11.0 at 2 hours of the 
OGGT. Of the 56 subjects, 18 had a normal glucose tolerance, 25 had prediabetes and 13 
diabetes. Baseline characteristics are shown in table I. No di"erences existed between 
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the di"erent groups concerning sex, age, BMI, bloodpressure, tobacco use and serum 
creatinine. HbA1c at baseline was signi!cantly di"erent between the groups (p<0.001) 
with a higher HbA1c in the (pre)diabetes groups than in the normal glucose tolerance 
group as could be expected. Results concerning SAF are shown in table II. SAF at 
baseline appeared to be higher for IGT and diabetes than for normal glucose tolerance. 
SAF was 2.04±0.55 for normal glucose tolerance, 2.27±0.71 for IGT and 2.54±2.54 for 
diabetes. However, these di"erences were not statistically signi!cant (p=0.18), probably 
as a result of the small number of subjects. Using ANOVA, the di"erences between the 
di"erent glucose tolerance groups are evaluated. Glucose at baseline, at 2 hours and 
also the increase in glucose were signi!cantly di"erent in the three glucose tolerance 
groups, with increasing glucose values from normal glucose tolerance to diabetes. No 
increase of SAF at 2 hours after oral intake of 75 gram glucose was found compared to 
baseline, even though glucose rose signi!cantly. SAF was 2.24±0.74 while fasting, and 
2.22±0.65 at 2 hours. The changes in SAF were independent of baseline SAF and level of 
glucose tolerance or change in glucose levels. 
 In conclusion, SAF is not immediately in#uenced by a rise in serum glucose levels as 
measured during an OGGT.
Table I: Baseline characteristics in the total group and di"erent glucose tolerance groups. Data 
are presented as mean ± SD or number of patients.
Normal Prediabetes Diabetes Total
N 18 25 13 56
Sex (males) 11 13 7 31
Age (years) 53,5±10,5 56,8±9,1 59,2±18,4 56,3±12,2
BMI (kg/m2) 30,6±6,3 30,8±5,5 31,0±5,7 30,8±5,7
Diast BP (mmHg) 86±14 85±13 83±12 85±13
Syst BP (mmHg) 139±16 140±13 143±25 140±17
Current smoking 5 4 2 11
Creatinin (µmol/L) 78,1±26,3 82,7±16,6 76,5±21,1 79,7±20,9
HbA1C (%) 5,5 ± 0,3 6,0 ± 0,3 6,2±0,3 5,9±0,4
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Table II: Results of OGTT on glucose and SAF in the total group and in the di"erent glucose 
tolerance groups. Di"erences between the 3 glucose tolerance groups were evaluated by 
ANOVA and depicted by the p-value.
Normal Prediabetes Diabetes Total p-value
Glucose 0 hr 5.1±0.26 6.0±0.46 6.93±0.93 5.9±0.87 <0.001
Glucose 2 hr 5.34±1.11 7.2±1.92 11.2±3.19 7.5±3.0 < 0.001
∆ Glucose 0.08±1.21 1.19±2.04 4.3±3.6 1.56±2.77 < 0.001
SAF 0 hr 2.04±0.55 2.27±0.71 2.54±0.96 2.25±0.74 0.18
SAF 2 hr 1.99±0.54 2.28±0.58 2.43±0.90 2.22±0.67 0.17
∆ SAF 0.04±1.65 0.01±0.25 0.11±0.18 0.033±0.21 0.25
The in!uence of an AGE-rich meal on skin auto!uorescence 
Food consumption may in#uence the accumulation of advanced glycation end 
products and thus SAF by several mechanisms. First of all, intake of food can result in 
glycaemic stress promoting the formation of AGE, especially when consisting of fast-
acting carbohydrates. Over prolonged periods this will enhance the tissue accumulation 
of AGE. Secondly, food is an exogenous source of AGE with broiled and fried food 
having markedly high AGE content.10,11 An AGE-rich meal might therefore in#uence the 
measurement of SAF, even when the short-acting glucose load has no e"ects on SAF, 
as discussed above. Stirban et al investigated the e"ect of a 580 kCal meal reported to 
have a intermediate AGE content of 8519 kU on SAF.12 Actually, both the caloric and AGE 
content is substantial. In this study, SAF was measured in a fasting state, as well as 2 and 
4 hours postprandially in 21 Caucasian subjects of which 10 were healthy and 11 had 
diabetes mellitus. A statistically signi!cant increase of 10% in SAF was found 2 hours 
postprandially from 1.97±0.62 AU to 2.17±0.62 U. In the diabetic subjects, SAF increased 
11.6% and glucose levels rose signi!cantly from 7.55 to 8.55 mmol/l at 2 hours. In 
healthy subjects, there was an 8.7 % increase in SAF at 2 hours while glucose did not 
signi!cantly rise (4.3 to 4.6). Individuals with diabetes had a slightly higher increase in 
SAF than the healthy individuals, 11.6 versus 8.7%. At 4 hours SAF had still not recovered 
and remained signi!cantly elevated compared to baseline: 2.16±0.72 (p<0.01). We did 
a similar study with a breakfast of 2 toasted slices of bread and cheese and 220 ml of 
caramelized pudding which has an estimated AGE content of 2700 kU. The AGE content 
was estimated by the same method as Stirban et al by using lists with the speci!c AGE 
contents of di"erent foods provided by Goldberg et al.13 In 9 healthy subjects (18-20 
years; 8 of the 9 subjects female) the SAF was measured before and at 1, 2 and 3 hours 
after the meal. At baseline SAF was 2.05±0.32. At 1 and 2 hours no rise in SAF was 
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observed with a SAF of 2.00±0.26 and 1.99±0.34 respectively. At 3 hours postprandially, 
however, the SAF was 9 % higher: 2.22±0.27 (p=0.038 in paired t-test). Results of both 
studies are presented in table III.
Table III: Results of an AGE rich meal on SAF. SAF is presented with mean ± SD. The statistical 
signi!cance of the di"erence in SAF before and after the meal is depicted by the p-value. 
AGE content N= SAF 0 hr SAF postprandial ∆ SAF p-value
Stirban 8518 kU 21 1.97±0.62 2.17±0.62 0.20 <0.01
Own results 2700 kU 9 2.05±0.32 2.22±0.27 0.15 0.038
In conclusion, meals rich in AGEs may result in a postprandial rise of SAF of maximally 
10%. Considering the lack of e"ect of glucose, described above, the meal-induced rise 
in SAF is probably due to the AGE content of the food. We therefore recommend not 
to measure skin auto#uorescence after an AGE rich meal. The e"ect of meals with a 
normal to low AGE content are as yet unknown. For more information concerning the 
AGE content of di"erent foods we refer to the available lists generated by Goldberg et 
al.13 In general, unprocessed fruits, non-toasted bread and liquids do not contain a high 
amount of AGEs. Clearly, a fasting state would abolish all potential in#uences from food 
consumption. If these meal induced e"ects would be eliminated, the predictive value of 
SAF would even surpass the earlier reported values.
 
Skin auto!uorescence and intermediate term glycaemic control 
measured by HbA1c 
While SAF represents a long term memory of glycaemic and oxidative stress, HbA1c 
represents a glycaemic memory over a period of 3 months. HbA1c is considered an 
early glycation product or Amadori product. In monitoring glycaemic control in diabetic 
patients, HbA1C is normally measured repeatedly over time. A correlation between 
HbA1c as an early glycation end product and SAF as a marker of tissue accumulation of 
advanced glycation end products can be expected. Several researchers indeed analysed 
the relationship between HbA1c values over time and AGE accumulation in tissue 
measured either directly in skin biopsies or non-invasively as SAF.14,15 
 Gerrits et al examined 452 patients with type 2 diabetes in a primary care setting 
who were well controlled (mean HbA1c 7%).15 She found that after 3.3 years of follow-up 
the accumulation of AGEs in skin measured as the rise in SAF at follow-up, had a weak, 
but signi!cant correlation with several integrated assessments of HbA1c (variance of 
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HbA1c, mean HbA1c, maximum HbA1c, and HbA1c at baseline). Regression coe$cients 
were <0.1; p≤0.025 (with addition of baseline SAF: overall adjusted R2 ~0.45; p<0.001).15 
The major determinants of SAF at follow-up after 3 years were baseline SAF and age. 
Duration of diabetes and smoking were not, and renal function was of marginal 
predictive value. 
 In a subpopulation of the Diabetes Control and Complications Trial (DCCT) skin 
biopsies of 216 patients with type 1 diabetes were examined for the presence of various 
AGEs.14,16 The biopsies were performed near the end of the trial. Of these subjects, 122 had 
been treated with intensive treatment and 94 had been treated conventionally during 
the previous 5 years. A strong positive relation between skin AGEs and age and duration 
of diabetes was found. Five years of intensive insulin therapy resulted in 24% lower 
HbA1c levels (7.1% in the intensive treatment group versus 9.3% in the conventional 
treatment group). Moreover, AGE’s measured in the skin biopsies were lower after 
intensive insulin treatment. In the intensive treatment group CML and pentosidine were 
9-13% and 9% lower respectively compared to the conventional treatment group. Cross 
linking of skin collagen was lower in the intensive treatment group resulting in a 24% 
higher acid soluble collagen and a 50% higher pepsin soluble collagen. The relationship 
between pentosidine and CML with di"erent integrated HbA1c markers (mean HbA1c 
up to biopsy, mean HbA1c over the past year, HbA1c nearest to biopsy and screening 
HbA1c) was assessed by performing univariate regression analysis. The relationship was 
again weak, but signi!cant with R2 9.6 and 13.8 for pentosidine and CML respectively 
with HbA1c nearest to biopsy; 8.9 and 16.1 for mean HbA1c up to biopsy.
 In conclusion, both Gerrits et al and Monnier et al found a weak relation between 
HbA1c and AGE’s in skin measured either as SAF or directly in skin biopsies. Monnier et 
al found HbA1c and skin AGE levels similarly lower in the group with 5 years of intensive 
treatment than in the conventional treatment group. The better glycaemic control no 
doubt resulted in a drop in glycaemic stress and (to a lesser extent) oxidative stress. 
 The issue of predicting diabetic complications by either HbA1c or AGEs measured 
in skin biopsies was also addressed by Monnier et al and Genuth et al.14,16 Monnier et 
al cross sectionally found that all AGE’s measured in the skin biopsies were signi!cantly 
associated with diabetic complications like retinopathy, nephropathy and neuropathy. 
After another 5 years of follow-up in this subpopulation of the DCCT, Genuth found 
that the combination of furosine (glycated collagen) and the AGE carboxymethyllysine 
(CML) predicted the risk of progression of retinopathy and nephropathy over the 10 year 
follow up period. The predictive value of skin AGEs remained after adjustment for HbA1c. 
Moreover, the predictive value of HbA1c completely disappeared after correction for 
furosine and CML. They concluded that accumulation of AGEs in tissue appears to be 
a major contributor in the development of diabetic complications and explains the 
Chapter 3
46
phenomenon of metabolic memory. In another study, Lutgers et al found that AGEs 
non-invasively measured as SAF proved to have predictive value far surpassing the 
value of HbA1c as established by several studies.2-4,14,17 The SAF added information to 
the classical UKPDS in which HbA1c, duration of diabetes and the classical risk factors 
for atherosclerosis are included.4
Value of skin auto!uorescence compared to IFG and HbA1c in diagnosing 
diabetes mellitus and IGT 
Maynard et al evaluated the value of SAF in detecting undiagnosed diabetes mellitus 
or impaired glucose tolerance (IGT) in a naïve population.18 They used an oral glucose 
tolerance test as the golden standard. A two hour OGTT of >7.8 mmol/l was used to 
de!ne IGT and values of >11.1 mmol/l de!ned diabetes mellitus. From a total of 351 
participants impaired glucose tolerance was found in 55 subjects and diabetes in 29 
subjects. A fasting glucose of >5.5 mmol/l had a sensitivity of 58% and a speci!city of 
77%. The authors chose to examine the sensitivity of HbA1c and SAF at this particular 
speci!city of 77%. At the speci!city of 77%, HbA1c>5.8 mmol/l did better with a 
sensitivity of 64%. SAF however was superior to both fasting glucose and HbA1c with a 
sensitivity of 75% at the prede!ned speci!city of 77% with was a statistically signi!cant 
improvement over blood tests (p<0.05). SAF, therefore, diagnosed 29% more subjects 
with abnormal glucose tolerance than fasting glucose and 17% more than HbA1c. The 
authors concluded that as 30 % of diabetics are undiagnosed the use of SAF might prove 
a powerful tool for early detection of abnormal glucose regulation and prevention of 
resulting damage.
 Preliminary, as yet unpublished results in a group of 57 subjects at risk for IGT 
or diabetes con!rmed the superiority of SAF above fasting glucose and HbA1c in 
classifying subjects in categories of normal glucose tolerance versus IGT and diabetes. 
Using SAF as part of a simple decision tree led to misclassi!cation of 4 out of 57 persons, 
while a fasting glucose >6 mmol/l would have led to misclassi!cation of 17 subjects and 
using glycated hemoglobin (HbA1c) values of >6% to misclassi!cation of 14 subjects. 
Validation studies in other and larger cohorts are ongoing (Smit A.J., preliminary results 
presented at ATTD 2009, Athens).
Conclusion
SAF is not signi!cantly in#uenced by short term glycaemic variations as measured 
during an OGTT. An AGE rich meal may result in a postprandial rise after 2-4 hours in 
SAF of approximately 10%. Intermediate term glycaemic variations as measured by 
multiple HbA1c measurements (over time) are weakly related to SAF both in type 1 
and type 2 DM, but dramatic improvements in HbA1c over years may be associated 
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with a lower level of AGE in skin. Moreover, skin AGE and SAF are strong predictors of 
diabetic complications and mortality with an accuracy far exceeding that of HbA1c and 
even that of most constituents of the UKPDS risk score. SAF is also a promising tool 
in diagnosing IGT and diabetes mellitus and proved to be more sensitive than either 
fasting glucose or HbA1c. 
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Dermal factors influencing 
measurement of skin 
autofluorescence
M.J. Noordzij, J.D. Lefrandt, R. Graaff, A.J. Smit




Background: Skin auto#uorescence (SAF) is a non-invasive marker of accumulation 
of advanced glycation endproducts. It predicts cardiovascular complications and 
mortality in diabetes and renal failure. We assessed the in#uence of potential common 
confounders in SAF measurement, by determining the e"ects of endogenous and 
exogenous local dermal changes by body creams, hyperemia, vasoconstriction and 
hydration.
Methods: SAF was measured before and after local administration of body lotion, day 
cream, sun screen or self browning cream and after attempts to remove these e"ects 
with alcohol swabs and washing. SAF was measured before and during three hyperemia 
maneuvers, vasoconstriction and on a dry and wet skin.
Results: The body lotion increased SAF by 18%. Day cream, sun screen and self browning 
cream gave an increase >100%. Except for body lotion, subsequent cleaning with 
alcohol swabs and washing with soap did not return SAF to baseline values. The e"ect 
of self browning cream persisted for 2 weeks and of sun screen for 4 days. Hyperemia 
caused by either a hot bath, capsicum cream or post occlusive reactive hyperemia gave 
a decrease in SAF of respectively 18, 22 and 2.3%. Vasoconstriction caused by immersing 
the arm in cold water gave a 10% increase. Hydration state did not in#uence SAF.
Conclusion: Measurement of SAF is strongly a"ected by several skin creams. This e"ect 
was often not fully corrected by alcohol swabs and washing with soap and may persist 
for many days. Marked hyperemia and vasoconstriction also in#uence SAF. We advise to 
avoid these potential error sources.




Advanced glycation end products (AGEs) accumulate in tissue over a lifetime, which 
is regarded as a process of normal ageing.1 It is well known that AGE accumulation 
is accelerated in diabetes mellitus and renal failure and contributes to long term 
complications and mortality.2-6 AGEs play a major pathogenetic role in many age-related 
diseases as a result of cross link formation and activation of cell membrane receptors 
including the receptor for AGE (RAGE) which leads to activation of several oxidative and 
in#ammatory pathways.7-9 
 Accumulation of AGEs in tissue can be assessed noninvasively with a technique named 
skin auto#uorescence (SAF), which uses UV light for the excitation of #uorophores in the 
skin. This technique has previously been validated by simultaneous measurements of 
SAF and assessments of speci!c AGE from skin biopsies of the dermal layer at the same 
measuring site.10 We earlier reported increased SAF in several groups of patients with 
increased AGEs formation such as diabetes mellitus, decreased clearance of AGEs such 
as renal failure and overt atherosclerotic disease such as patients with stable coronary 
artery disease.5,11,12 Moreover, SAF proved to be a powerful predictor of complications 
and mortality in diabetes and renal failure.2,3,5 
 Clinical application of SAF to estimate risk in diabetes mellitus and renal failure is 
gaining ground. For adequate application of SAF it is important to know what factors 
might in#uence or disturb the measurement. The e"ect of excitation wavelength and 
skin color in general have been previously studied and reported.13,14 Also, the in#uence 
of an AGE rich meal resulting in a temporary postprandial rise of 10% has been reported 
by Stirban et al.15 The present study addresses the in#uence on SAF measurements of 
potential common confounders inducing local exogenous and endogenous dermal 
changes. First, the in#uences of several skin sun protecting and tanning creams on SAF 
are evaluated. Second, we measured the e"ects of hyperemia and vasoconstriction. 
Third, the e"ect of wetness of the skin was addressed. 
MATERIALS AND METHODS
Subjects
Healthy volunteers from the normal population were recruited to participate. Informed 
consent was obtained. Inclusion criteria were Caucasian race and an age between 18 
and 65 years. Exclusion criteria were the use of medication, a prior medical history or 




To assess tissue AGE accumulation, SAF was measured with the AGE Reader™ (DiagnOptics 
Technologies BV, Groningen, the Netherlands). The AGE Reader™ is a desk-top device 
that uses the characteristic #uorescent properties of some AGEs to estimate the level of 
AGE accumulation in the skin. Technical details of this non-invasive device concerning 
the optical technique have been described more extensively elsewhere.14,10 In short, the 
AGE Reader illuminates a skin surface of 4 cm2 guarded against surrounding light with 
an excitation light source with a peak excitation of 370 nm. This wavelength is in the 
UVA spectrum. Emission light in the wavelength range of 420-600 nm (#uorescence) 
and excitation light that is re#ected by the skin with a wavelength range of 300-420 nm 
from the skin is measured with a spectrometer. SAF was determined from the ratio 
between the emission light and the re#ected excitation light, using the AGE Reader 
software version 2.2. In the current series of experiments, the forearm was positioned 
on top of the device in the usual manner as described by the manufacturer. For each SAF 
value, a series of three consecutive measurements was carried out, which took less than 
a minute time. The mean of these three consecutive measurements was calculated and 
used in the analyses.
Study protocol
First, several representatives of dermal creams were tested. Body lotion (Etos®), facial 
day cream (Etos®), water resistant sun screen with a UVA/UVB protective value of 50 SPF 
(Etos®) and self browning cream containing dihydroxyaceton (DHA) manufactured by 
Vichy® were evaluated. Speci!cations of the contents of the creams are provided in the 
appendix. Beforehand, we tested the auto#uorescent and light absorbing properties 
of the creams itself on a calibration material which has zero auto#uorescence and a 
practically 90-100% re#ectance. Then, at baseline, a standard triple measurement of SAF 
was performed before application of the cream on the lower arm of the study subjects. 
SAF was again measured 5-10 minutes after application of the cream permitting time 
for the cream to fully draw into the skin. After this, SAF was measured after rubbing with 
an alcohol swipe and subsequently after washing the skin with water and soap in an 
attempt to clear the skin of the applied cream. Subsequent alcohol swipes or washing 
were not done in the case of browning cream. Finally, we assessed the natural time for 
the e"ect of sunscreen and DHA cream to wear o". We chose these 2 creams as they 
proved in previous experience and in the initial steps to have the most potent and 
persistent e"ects on SAF. The cream was applied and subsequently SAF was measured 
daily with subjects performing their normal daily routine. 
 Second, we investigated the e"ect of hyperaemia and vasoconstriction. Hyperaemia 
was elicited in several ways. First, by immersing the arm in warm water of 42 degrees 
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for 4 minutes. SAF was measured directly after drying the skin with a towel. Second, 
by applying a tourniquet for 4 minutes and measuring SAF during the post-occlusive 
reactive hyperaemia (PORH)/reperfusion phase 2 minutes after releasing the tourniquet. 
Third, by applying capsicum cream locally on the measurement site for 4 minutes, 
which results in an outspoken local vasodilatation of the skin within several minutes of 
application. SAF was measured after removal of the cream. Intrinsic auto#uorescence 
and absorbance e"ects of capsicum cream are shown below. Vasoconstriction was 
induced by immersing the arm in cold water of 12 degrees for 4 minutes. After drying 
the arm with a towel, skin AF was immediately measured. 
 Last, the in#uence of local dermal wetness was addressed by measuring SAF before 
and directly after application of a wet cotton gauze for 5 minutes. After removal of the 
gauze the skin was not dried before SAF measurement.
Statistical analysis
Data were gathered in a database (SPSS 15-0, SPSS Inc, Chicago, Illinois, USA). Normal 
distribution of the variables was tested by Kolmorgorov-Smirnov tests. Descriptive 
statistics are, therefore, presented as mean with standard deviation in case of normal 
distribution, otherwise as median with interquartile range or as number of patients. A 
paired student t- test was used for normally distributed parameters and a paired Mann 
Whitney U test was used for parameters with a skewed distribution. We performed a 
power analysis and determined that 11 subjects were needed to detect a 5% di"erence 
in SAF (β=0.8, α=0.05).
RESULTS
Subject characteristics
We gathered 39 study subjects. All subjects were Caucasian, healthy and used no 
medication as de!ned by the inclusion and exclusion criteria. The median age was 31 
years. Twenty subjects (51%) were male. Eight subjects (20%) were current smokers. 
Mean BMI was 23.4 kg/m2. Mean blood pressure was 124/76 mmHg. At baseline median 
an SAF was 1.69±0.33 which is in agreement with the expected SAF of 1.69 for this mean 
age,16 and mean skin UV re#ectance was 17%±4.9%,.
E#ect of di#erent body creams
The intrinsic #uorescent and re#ectance properties of the di"erent creams as tested in 
vitro against the white standard are presented in table I. There were major di"erences 
in both (auto)#uorescence and re#ectance between the creams. While body lotion 
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appeared to have negligible #uoresent properties, daycream and sun screen were highly 
#uorescent. Day cream and sun screen had very high absorbent properties resulting in 
a very low re#ectance levels of 1.5% and 2.0%, respectively. Self browning cream and 
capsicum cream showed moderate auto#uorescence and little UV absorption.
 The e"ects of di"erent body creams on lower arm SAF measurements are shown 
in table II. Body lotion gave an 18% increase in SAF. Facial day cream and sun screen, 
however, gave a 139 and 111% increase of SAF, respectively. Self browning body cream 
containing DHA even gave a tripling in SAF. This e"ect was accompanied by a marked: 
drop in re#ectance for both facial day cream, sunscreen and self browning cream. For 
these 3 creams re#ectance was lowered from 17% to approximately 3%. 
Table I: Measurement of intrinsic #uorescence and re#ectance of creams applied on calibration 
material with zero auto#uorescence and 90-100 % re#ectance. Data are denoted as mean (±SD)
N Auto!uorescence (AU) Re!ectance (%)
Body lotion 2 0.076 (0.034) 79.5 (0.71)
Day cream 4 10.85 (1.32) 1.53 (0.096)
Sun screen 3 3.13 (1.00) 2.03 (0.40)
Self browning cream 4 0.90 (0.091) 59.5 (1.00)
Capsicum cream 3 1.03 (0.23) 56.7 (3.2)
Table II: E"ect of the di"erent creams on SAF (standard deviation).
SAF (AU) Re!ectance (%)
N Baseline Cream % increase Baseline Cream % decrease
Body lotion 14 1.81 (0.25) 2.14 (0.40) 18* 16 (5) 14 (5) 12.5*
Day cream 8 1.86 (0.41) 4.45 (0.93) 139* 17 (5) 3 (1) 82.4*
Sun screen 10 1.61 (0.21) 3.40 (1.16) 111* 17 (6) 2 (1) 88.2*
DHA cream 3 1.95 (0.45) 7.77 (1.63) 298* 16 (6) 8 (3) 50*
* denotes statistical signi!cance with a p-value of <0.001
 
The e"ect of cleaning the skin by rubbing with an alcohol swab and additional rinsing 
with water and soap are presented in !gure 1. It proved to be relatively easy to eliminate 
the e"ects of body lotion on SAF: the e"ect on SAF was largely reversed by an alcohol 
swab. After an additional washing, no di"erence with the baseline SAF level was found. 
Alcohol swabs only marginally reversed the increase in SAF induced by the day cream 
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and sunscreen. Even additional careful washing of the arm with water and soap did not 
result in return of SAF to baseline values. With day cream, alcohol swabs gave a 33% fall 
of SAF towards baseline levels, and another 17% by washing. After the alcohol swab 
and washing SAF was still elevated compared to baseline: 2.47±0.64 versus 1.86±0.41 
(p=0.002). Sunscreen proved to be the cream with the most persistent e"ects on SAF. 
Here, alcohol swabs gave only a 13% fall of SAF towards baseline levels, and additional 
washing another 19%. After the alcohol swab and washing SAF was still elevated from 
baseline: 2.42±0.32 vs. 1.61±0.21 (p<0.000). Re#ectance also remained signi!cantly 
lowered in spite of alcohol swaps and washing for both day cream and sun screen. We 
assessed the natural wear-o" e"ect of sunscreen and self browning cream in 3 subjects 
to provide an indication. It took approximately 4 days with sunscreen, and 2 weeks with 
the self browning cream before SAF had returned to baseline levels (!gure 2).
Figure 1: E"ects of cream, alcohol swab and washing.
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Figure 2: Wear o" e"ect of self browning cream and sunscreen.
E#ect of vasodilatation and vasoconstriction
The e"ect of vasodilation on SAF was tested by a hot bath, capsicum cream and 
reperfusion after release of a tourniquet. Results are shown in table III. Capsicum cream 
and a hot bath resulted in an outspoken visual hyperaemia, while reperfusion did not. 
SAF was lowered by 22% for capsicum cream and 18% after a hot bath. Reperfusion only 
resulted in a non-signi!cant drop of 2.3% in SAF. During all hyperaemia manoeuvres, 
UV re#ectance was not a"ected. Vasoconstriction caused by a cold bath caused a 10% 
higher SAF and a decrease in re#ectance from 16.8 to 14.6 % (p=0.009). 
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Table III. E"ect of hyperaemia and vasoconstriction on SAF (standard deviation). The p-value 




Cold bath 10 1.73 (0.33) 1.90 (0.38) +10 0.026*
Hot bath 10 1.73 (0.33) 1.41 (0.49) - 18 0.002*
Capsicum cream 12 1.76 (0.38) 1.37 (0.27) - 22 0.002*
Reperfusion 18 1.71 (0.36) 1.67 (0.33) - 2.3 0.11
E#ect of hydration state of the skin
We measured SAF on a normal dry skin and subsequently on a wet skin after 5 minutes 
of application of a wet cotton gauze in 16 subjects. There was no di"erence in SAF 
between a dry and wet skin. On the dry skin SAF was 1.99 (±0.44) and on the wet skin 
2.02 (±0.50), p=0.57. Re#ectance also was not di"erent: 17.9 versus 18.3%, p=0.51. 
DISCUSSION
Our study aims to clarify pitfalls in the measurement of SAF. We show that both the 
application of several creams as well as extreme vasodilatation and vasoconstriction 
at the measurement site may have a major e"ect on SAF. Creams and extreme 
vasoconstriction can result in falsely high SAF whereas vasodilatation causes a lower 
value. This has to be taken into consideration when a SAF measurement is performed. 
Creams
The increase in SAF after application of creams can be attributed to several di"erent 
mechanisms. First of all, a cream may have #uorescent properties of its own as shown 
in table I. Secondly, some creams like day cream and sunscreen are designed to absorb 
UVA and UVB radiation to protect the skin against the long term harmful e"ects on skin 
photo-aging and the development of skin cancer. SAF is the ratio between the emission 
light (auto#uorescence) and the re#ected excitation light (with a peak wavelength at 
370 nm in the UVA spectrum). Creams like sunscreen and day cream lead to a severe 
drop in the re#ected excitation light, as shown by the lowering of re#ectance. Because 
auto#uorescence occurs by de!nition at higher wavelengths and, thus, is less in#uenced, 
the SAF as a ratio between the two would rise. Similarly, creams that show absorbion 
of the excitation light will cause a lower SAF. Third, creams may cause changes in the 
skin itself. As for self browning cream DHA binds to the stratum corneum leading to 
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chemical changes. This leads to a brown discoloration of the skin and an increased 
absorption of UVA light. As the self browning cream itself did not show marked 
intrinsic auto#uorescent or absorbent properties, the large e"ects on SAF are probably 
explained by these chemical changes in the stratum corneum with resulting #uorescent 
and absorbent properties. Creams in#uencing capillary blood #ow and hydration state 
may also result in dermal changes that a"ect SAF. In conclusion, creams may directly or 
indirectly in#uence SAF measurements. 
 We also showed that the e"ect of creams on SAF is not completely reversed by 
alcohol swaps or washing with water and soap. Besides that, it takes 4 days for sunscreen 
e"ects on SAF to naturally wear o", and even 2 weeks for self browning cream. The 
water resistant sunscreen we used was designed to not be easily washed o", but it is 
surprising to see that the e"ect persisted for 4 days. Self browning cream containing 
DHA chemically binds to the stratum corneum. The long delay of SAF to return to 
baseline levels is therefore, mainly determined by the turnover or rather wear o" time 
of the stratum.
Blood !ow
Local skin blood #ow also in#uences SAF measurement. This phenomenon can be 
understood by the fact that haemoglobin has absorbent properties over a broad range 
in both the excitation and emission parts of the auto#uorescent spectrum used during 
SAF measurements. As an increase in the amount of dermal blood causes lower values 
of SAF, we may conclude that more of this emission light (#uorescence) is absorbed 
compared to the absorbance of re#ected excitation light. This can also be observed by 
the virtually unchanged re#ected excitation light. Vasoconstriction leads to the reverse 
e"ect, in other words a higher SAF value. In our study, the e"ects were seen only when 
extreme vasodilatation was induced. Capsicum cream and the warm bath both led 
to a clearly visible hyperaemia and gave 22% and 18% decrease in SAF. Reperfusion 
after applying a tourniquet only led to a 2% decrease which was not signi!cant. In this 
situation, there also was no visible hyperaemia. One must keep in mind that the AGE 
Reader only penetrates the skin to a depth of 0.1-0.2 mm and, therefore, only the e"ect 
of the most super!cial capillaries are measured, mainly nutrient skin capillaries of the 
upper and lower dermal plexus.17 This may explain the relatively modest e"ect of skin 
blood #ow on SAF. With the post occlusive reactive hyperemia procedure, the resulting 
ischemia may have in#uenced the NAD/NADH balance. NADH has auto#uorescent 
properties in the same wavelength as AGE’s.18 Surprisingly, during and after ischemia 
SAF was hardly in#uenced. This may be due to the fact that NADH #uorescence is found 
more in the epidermis where oxygen is provided by direct di"usion from the air, and 
therefore less in#uenced by arterial occlusion caused by a tourniquet. We, therefore, 
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are inclined to believe that NADH hardly in#uences SAF measurement. Vasoconstriction 
caused by a cold bath of 12 degrees led to a 10% increase in SAF. We conclude that only 
extreme vasodilatation and vasoconstriction signi!cantly a"ect SAF. 
Limitations
We are aware that we only examined a limited number of creams. A list of creams 
without e"ects on SAF cannot be provided. Results in the tested creams are, however, 
very marked and lead to the conclusion that caution in SAF measurements after the 
local use of any cream is necessary, especially for sun protecting creams or skin tanners. 
A low re#ectance level in a normal white Caucasian skin should raise the suspicion of 
the recent use of such a cream. The manual provided by the manufacturer of the AGE 
Reader, therefore, advises not to measure SAF after recent use of skin creams. Perhaps 
some other spectral characteristics other than the re#ectance level may also become 
helpful in detection of previous use of cosmetic or other preparations a"ecting a SAF 
measurement.
 Reperfusion of the arm after application of a tourniquet did not lead to a signi!cant 
decrease, while a warm bath and capsicum cream did. How to explain this discrepancy? 
Maybe reperfusion did not lead to enough vasodilatation to cause an e"ect. Also, 
measurements were taken 2 minutes after release of the tourniquet and capillary #ow 
may have already been past the point of peak reperfusion capillary #ow. This may be 
supported by the fact that a visual hyperaemia was seen after both a hot bath and 
capsicum cream, while this was not visible after the tourniquet release. 
 Another limitation of our study is that the situations in which we tested hyperaemia 
and vasoconstriction were extreme and do not represent normal physiological 
situations. Probably the e"ect of capillary blood #ow in normal day life will be much 
less outspoken and may be even neglectable. In previous studies presumed seasonal 
variations in super!cial skin #ow were associated with a VC of 5-6% in SAF.11 
Implications
We conclude that a warning not to use any cream in the days before measurement and for 
sunscreens and sun tanners even in the 2 weeks before measurement seems necessary 
to assure accuracy. Furthermore, we advise to perform measurements with the arm in 
a normal perfusion state. The manual provided by the manufacturer of the AGE Reader 
already advises not to measure SAF after recent use of skin creams. Currently, attempts 
are made to have the device provide warnings about detection of previous possible use 
of skin creams, using the e"ects on re#ectance and other spectral changes. 
 In earlier studies the value of SAF in prediction of diabetic complications and 
mortality has been well established. Also in dialysis patients, SAF has shown predictive 
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value on mortality. When confounding factors like body creams and extreme perfusion 
states of the measured arm would be cautiously eliminated, the predictive value of SAF 
may even surpass the earlier reported values. 
Conclusion
This study aims to clarify pitfalls in the measurement of SAF. Local use of body creams can 
result in falsely high values of the measured SAF, accompanied by a drop in re#ectance. 
Especially creams that absorb UVA light, chemically react with the stratum corneum 
or have auto#uorescent properties of their own may a"ect SAF, persisting for days. 
An extremely low re#ectance in a normal white skin in combination with a high SAF 
value should raise the suspicion of the recent use of a disturbing cream. Extreme local 
vasodilatation and vasoconstriction also a"ect SAF, but to a lesser extent, and should be 
avoided at the time of measurement. 
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Speci$cations of the contents of the creams used in this study
Body lotion 
Manufactured by Etos® BV Beverwijk
Aqua, dicaprylyl carbonate, para$num liquidum, glycerine, stearic acid, dimethicone, 
cetearyl alcohol, sodium lactate, sodium PCA, glycine, fructose, urea, niacinamide, 
inositol, sodium benzoate, lactic acid, hydrogenated polydecene, tocopheyl acetate, 
parfum, phenoxyethanol, benzoic acid, dehydroacetic acid, phenethyl alcohol, PPG-
2 methyl ether, methylisothiazolinone, PEG-40 hydrogenated castor oil, sodium 
hydroxide, tetra sodium EDTA, sodium cetearyl sulphate, acrylates/C10-30 alkyl acrylate 
crosspolymer, xanthan gum, maris sal.
Day cream
Manufactured by Etos® BV Beverwijk
aqua, cyclopentasiloxane, glycerin, glyceryl stearate SE, propylheptyl caprylate, 
cetearyl alcohol, terminalia catappa extract, propylene glycol, avena sativa kernel 
extract, titanium dioxide, palmitic acid, stearic acid, hibiscus abelmoschus seed 
extract, sambucus nigra extract, butylene glycol, tocopheryl acetate, butyrospermum 
parkii butter, parfum, xanthan gum, sodium acrylate/sodium acryloyldimethyl taurate 
copolymer, isohexadecane, retinyl palmitate, arachis hypogaea oil, PVP, polysorbate 80, 
acrylates/C10-30 alkyl acrylate crosspolymer, sodium hydroxide, benzyl alcohol, tannic 
acid, linalool, methylchloroisothiazolinone, methylisothiazolinone, CI 15985, CI17200.
Sunscreen, water resistant, spf 50
Manufactured by Etos® BV Beverwijk 
Aqua, octocryleen, ethylhexyl salicylate, butyl methoxydibenzoymethane, 
methyleen bis-benzotriazolyl tetramethylbutylphenol, C12-15 alkyl benzoate, 
glycerine, glyceryl stearate, PEG 100 stearate, tricontanyl PVP, ethylhexyl triazone, 
parfum, cyclopentasiloxane, cetyl alcohol, bis-ethylhexyloxyphenol methoxyphenyl 
triazine, decyl glucoside, tocopheryl acetate, biosacheride gum-1, benzyl salicylate, 
xanthan gum, bisabolol, polyacrylamide, C13-14 isopara$n, linalool, limonene, 
butylphenyl methylpropional, alpha-isomethyl ionone, hexyl cinnamal, disodium 
EDTA, laureth-7, propylene glycol, benzyl alcohol, citronellol, citric acid, PEG-8, 
benzyl benzoate, hydroxyisohexyl 3-cyclohexane carboxaldehyde, tocopherol, 





Aqua, propyleneglycol, dihydroxyacetone, ethylhexyl salicylate, ethylhexyl metho- 
xycinnamate, C12-15 alkyl benzoate, cyclopentasiloxane, alcohol denat., glycerin, 
arachidyl alcohol, PEG-L00 stearate, di-C12-13 alkyl tartrate, glyceryl stearate, 
dimethicone, arachidyl glucoside, behenyl alcohol, butylparaben, C13-14 isopara$n, 
disodium EDTA, ethylparaben, glycine soja/soybean oil, isobutylparaben, Laureth-7, 
methylparaben, phenoxyethanol, polyacrylamide, propylparaben, tocopherol, 
parfum.
Cremor capsici
Manufactured by Pharmachemie BV®
10% ethyleenglycolmonosalicylate, 0.1% histamindihydrochloride, 1% methyl- 
nicotinate, 0.1% capsicumextract (Spanish pepper extract), stearinic acid, sorbitol, 
triethanolamine, methylparahydrocybenzoate, cetylstearylaclcohol, sodiumlauryl-
sulphate.
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Skin autofluorescence is  
increased in patients with  
carotid artery stenosis and 
peripheral artery disease
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Objectives: Advanced glycation end products (AGEs) have a pivotal role in 
atherosclerosis. We evaluated skin auto#uorescence (SAF), a non-invasive measurement 
of tissue AGE accumulation, in patients with carotid artery stenosis with and without 
coexisting peripheral artery occlusive disease (PAOD).
Materials and methods: SAF was measured using the AGE Reader™ in 56 patients 
with carotid artery stenosis and in 56 age- and sex-matched healthy controls without 
diabetes, renal dysfunction or known atherosclerotic disease.
Results: SAF was higher in patients with carotid artery stenosis compared to the control 
group: mean 2.81 versus 2.46 (p=0.002), but especially in the younger age group of 50 
to 60 years old: mean 2.82 versus 1.94 (p=0.000). Patients with carotid artery stenosis 
and PAOD proved to have an even higher SAF than patients with carotid artery stenosis 
only: mean 3.28 versus 2.66 (p=0.003). Backward linear regression analysis showed that 
age, smoking, diabetes mellitus, renal function and the presence of PAOD were the 
determinants of SAF, but carotid artery stenosis was not. 
Conclusion: SAF is increased in patients with carotid artery stenosis and PAOD. The 
univariate and multivariate associations of SAF with age, smoking, diabetes, renal 
insu$ciency and PAOD suggest that increased SAF can be seen as an indicator of 
widespread atherosclerosis. 




Advanced glycation end products (AGEs) accumulate in long lived tissue during lifetime, 
which is regarded as a process of normal ageing. AGE accumulation results from a 
combination of hyperglycaemia, hyperlipaemia, oxidative/carbonyl stress and also 
decreased renal clearance of AGE precursors. Accelerated AGE accumulation is therefore 
seen in diabetes mellitus and renal failure and contributes to long term complications 
and mortality.1-3 AGEs also play a major pathogenetic role in atherosclerosis.4-7 Cross 
linking of AGEs with collagen and elastin within the vascular wall contributes to arterial 
sti"ness.1,5,6 AGEs also alter the extracellular matrix and promote atheroma formation.6-8 
Furthermore, activation of cell membrane receptors including the receptor for AGE 
(RAGE) leads to activation of several oxidative and in#ammatory pathways.1,7,8 This 
cascade leads to endothelial dysfunction, vascular in#ammation and production of 
reactive oxygen species.1 These mechanisms accelerate the formation of atherosclerosis.1 
Finally, AGE accumulation and overexpression of RAGE within the plaque may promote 
plaque instability.9
 Accumulation of AGEs in tissue can be assessed through illumination of the skin, a 
technique named skin auto#uorescence (SAF), which has previously been validated by 
simultaneous measurements of SAF and contents of speci!c AGE assessments in skin 
biopsies.10-12 Although the #uorescent characteristics in this method are not speci!c for 
#uorescent AGE, multiple validation studies have shown convincingly and consistently 
that SAF has a strong correlation with speci!c AGE content in skin biopsies.10-12 The 
correlation between SAF with the #uorescent AGE pentosidine is very high: r=0.87. 
Surprisingly, not only #uorescent AGE (pentosidine) but also non #uorescent AGE 
(N-carboxymethyl-lysine (CML) and N-carboxyethyl-lysine (CEL)) in the skin biopsies 
showed great correlation with SAF. Skin AGE content explained the major part of the 
variance (up to 76%) in the SAF signal in a pooled analysis of three validation studies.11 
We earlier reported increased SAF in several groups of patients with increased AGEs 
formation such as diabetes mellitus,3,13 decreased clearance of AGEs such as renal 
failure14 and overt atherosclerotic disease such as patients with stable coronary artery 
disease.15 Earlier studies have already demonstrated an elevated serum level of AGEs in 
patients with carotid disease; a positive association between intima media thickness 
(IMT) and serum levels of AGEs were found in population with renal insu$ciency 
starting dialysis.16 Baumann et al showed that the AGE N-epsilon-carboxymethyllysine 
(CML) is present in the subendothelial space of atherosclerotic human carotid artery 
material of normoglycaemic subjects with a mean age of 50 years.17 However, the level 
of SAF as a measurement of increased tissue accumulation of AGEs rather than plasma 
AGEs level has not yet been studied in patients with carotid artery stenosis. Therefore, 
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the present study evaluates SAF in patients with atherosclerotic carotid artery stenosis 
with or without coexisting peripheral arterial disease. The possible value of SAF as a risk 
indicator in this speci!c cohort of patients is further discussed.
MATERIALS AND METHODS
Subjects
Between October 2007 and May 2008 56 consecutive patients with carotid artery 
stenosis admitted to the outpatient clinic of the Department of Surgery (Division of 
Vascular Surgery) in our tertiary referral hospital participated in the study after informed 
consent was obtained. The degree of stenosis and basic morphologic features of the 
plaque were evaluated by duplex ultrasound. Duplex ultrasound was performed in the 
clinical setting as part of standard medical care. This was performed by one observer, 
a specialized sonographer of the department of vascular surgery of our university 
hospital. Inclusion criteria were the presence of a symptomatic stenosis of 70-99% (or 
less in case of ulcerative soft plaques) or an asymptomatic stenosis of 80-99%. There 
were no exclusion criteria. 56 age- and sex-matched controls were recruited at the 
outpatient clinic of the Department of Anaesthesiology for preoperative evaluation 
prior to an elective non-cardiovascular related surgical procedure. Control patients were 
eligible if they did not have a history of diabetes, cardiovascular disease or renal disease. 
Carotid ultrasound was not performed in the control group.
Study protocol
In both groups, classical cardiovascular risk factors as well as other factors that are 
known to in#uence AGE accumulation were inventoried: body mass index, smoking 
status, diabetes mellitus, hypertension (de!ned as a blood pressure of more than 140/90 
mmHg or the use of antihypertensive medication), hypercholesterolemia (depicted 
by the use of statins), renal function and the presence of coronary artery disease and 
peripheral artery occlusive disease (PAOD). SAF was measured in carotid artery stenosis 
and control patients.
Assessment of skin auto!uorescence
SAF was measured with the AGE Reader™ (DiagnOptics Technologies BV, Groningen, 
the Netherlands). The AGE Reader™ is a desk-top device that uses the characteristic 
#uorescent properties of some AGEs to estimate the level of AGE accumulation in the 
skin. Technical details of this non-invasive device concerning the optical technique have 
been described more extensively elsewhere.11 In short, the AGE Reader illuminates a 
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skin surface of 4 cm2 guarded against surrounding light with an excitation light source 
with a peak excitation of 370 nm. Emission light (#uorescence in the wavelength of 420-
600 nm) and re#ected excitation light (with a wavelength of 300-420 nm) from the skin 
is measured with a spectrometer. SAF is calculated as the ratio between the emission 
light and re#ected excitation light, multiplied by 100 and expressed in arbitrary units. 
 In the current series of experiments, the right forearm was positioned on top of 
the device. The right forearm is the standard measuring site for SAF as it is the most 
practical site and auto#uorescence is believed to be uniformly distributed throughout 
the body. A series of three consecutive measurements was carried out, which took less 
than a minute time. The mean SAF of three consecutive measurements was calculated 
and used in the analyses. An earlier validation study showed an intra individual Altman 
error percentage of 5.03% with SAF measurements taken over 1 single day and an 
Altman error percentage of 5.87% over seasonal variation.11 Between subjects, SAF has 
a standard deviation of approximately 0.5 AU.18 SAF shows a linear increase with age of 
0.023 AU per year for subjects up to 70 years.18 Gender had no in#uence on SAF in non-
smokers. In smokers, SAF was 0.2 AU higher in females.18 The SAF measurement with the 
AGE reader is independent of skin colour when re#ectance values are above 12% as was 
the case in all of the study participants.18 Measurements were performed in fasting state 
as previous studies showed a postprandial rise up to 12%.19-20 
Statistical analysis
Power analysis was based on the reference values for SAF provided by Koetsier et al.18 
Using a mean SAF of 2.5 AU with a SD of 0.55 AU, 56 patients and 56 controls were needed 
to detect a di"erence of at least 0.3 AU (=12 percent) with a power of 80% and a p-value 
<0.05. Data were prospectively gathered in a database (SPSS 15-0, SPSS Inc, Chicago, 
Illinois, USA). Distribution of variables was tested by the Kolmorgorov-Smirnov test. All 
parameters showed a normal distribution. Descriptive statistics are therefore presented 
as mean with standard deviation or as number of patients. For comparison between 
continuous variables the t-test was used. For categorical variables the Fisher exact 
test was used. Correlations between variables were analysed by Pearson’s correlation. 
Subsequently, backward linear regression analysis was performed to determine the 






Patient characteristics are summarized in table I. The mean age of both groups was 
approximately 69 years. All patients were Caucasian and thirty-seven patients (66%) 
were male in both groups. As expected, the presence of traditional cardiovascular risk 
factors as well as established coronary artery or peripheral artery occlusive disease 
(PAOD) was signi!cantly higher in the patients with carotid artery stenosis. Twenty 
!ve patients with carotid artery stenosis were current smokers compared to 9 in the 
control group. Mean BMI was not di"erent between the groups, both approximately 
27.5 kg/m2. Twelve patients (21%) had diabetes mellitus and three of them used 
insulin therapy. Mean blood pressure was 153/80 mmHg in the patients with carotid 
artery disease and 156/84 mmHg in the control group. Diastolic blood pressure was 
signi!cantly higher in the control group. Nearly all patients with carotid artery stenosis 
had hypertension (n=54) and nearly half of them used more than two antihypertensive 
agents. Signi!cantly fewer subjects in the control group had hypertension (n=43) but 
only 18 of these hypertensive controls received antihypertensive medication. Statins 
were used by 49 patients with carotid artery stenosis (87.5%), while only one subject in 
the control group was on statin therapy. All patients with carotid artery stenosis used 
either antiplatelet therapy (n=50) or an oral vitamin K inhibitor (n=6). Mean serum 
creatinin was 90 in the patients with carotid artery stenosis and 96 umol/liter in the 
control group. Nearly half of the patients with carotid artery stenosis also had either 
coronary artery disease or peripheral artery occlusive disease (n=26). Of the 56 patients 
with carotid artery disease, 14 had coexisting PAOD and 17 coexisting coronary artery 
disease. As a consequence of the exclusion criteria, none of the control group patients 
had atherosclerotic manifestations.
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Table I: Baseline characteristics presented as mean (standard deviation), median (interquartile 
range) or as number of patients (%).
Characteristic Carotid artery stenosis Control subjects p-value
N 56 56
Age (years) 69.0 (7.8) 68.9 (7.9) 0.96
Male sex 37 (66%) 37 (66%) 1.0
Current smoker 25 (45%) 9 (16%) 0.002
BMI (kg/m2) 27.2 (4.9) 27.8 (3.9) 0.49
Diabetes mellitus 12 (21%) 0 0.001
Diabetes mellitus requiring insulin 3 (5%) 0 0.24
Systolic blood pressure 153 (22) 156 (22) 0.47
Diastolic blood pressure 80 (74-89) 84 (80-89) 0.016
Hypertension (>140/90 mmHg/med) 54 (96%) 43 (77%) 0.004
Antihypertensive medication 52 (93%) 18 (32%) <0.001
>2 antihypertensive agents 22 (39%) 2 (4%) <0.001
Statin therapy 49 (88%) 1 (2%) <0.001
Serum creatinine 90.1 (34.5) 95.6 (15.7) 0.28
Renal clearance (MDRD) 84 (37) 73 (16.7) 0.050
Anti platelet therapy 50 (89%) 0 <0.001
Coronary artery disease 17 (30%) 0 <0.001
PAOD 14 (25%) 0 <0.001
Coronary artery disease and/or PAOD 26 (46%) 0 <0.001
Skin auto!uorescence
Overall, SAF was signi!cantly higher in the patients with carotid artery stenosis (mean 
SAF 2.81) compared to the control group (mean SAF 2.46) (Table II). After strati!cation for 
age, the di"erence in SAF was primarily observed in the age category of 50 to 60 years: 
a mean SAF of 2.82 in the carotid artery stenosis patients versus a mean SAF of 1.94 in 
the controls. (Table II). After exclusion of patients with diabetes mellitus the di"erences 
in SAF remained signi!cant in the total group with carotid artery stenosis as well as in 
the age subgroup of 50 to 60 years old. Figure 1 shows that the control group exhibits 
the natural increase of SAF with advancing age (r=0.52, p<0.001). In the patient group 
with carotid artery stenosis, the relationship between SAF and age has disappeared as 
younger patients already have a high SAF (r=0.094, p=0.49). 
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Figure 1: Scatter plot showing SAF in relation to age in patients with carotid artery stenosis and 
controls. Circles denote control subjects, triangles patients with carotid artery stenosis, stars 
patients with carotid artery stenosis and coexisting PAOD.
Trend lines are shown for controls (dotted line) and carotid artery stenosis (continuous line). The control group 
exhibits the natural increase of SAF with advancing age. In the patient group with carotid artery stenosis, the 
relationship between SAF and age has disappeared. Patients with carotid artery stenosis and coexisting PAOD 
show a higher SAF than the control subjects and the patients with carotid artery disease only.
Within the carotid artery stenosis group, the degree of stenosis did not in#uence 
SAF (p=0.71). Also, no di"erence in SAF was found between the asymptomatic and 
symptomatic patients with carotid artery stenosis (p=0.21). 
 PAOD proved to be strongly associated with a high SAF. Patients with PAOD had a 
higher SAF than patients without peripheral arterial occlusive disease. When comparing 
SAF of patients with carotid artery stenosis and PAOD to SAF in the control group, 
SAF was 3.28 (0.66) versus 2.46 (0.57) with a p value of 0.000 (table II). Even within the 
group of carotid artery stenosis, SAF was signi!cantly higher when there was coexisting 
PAOD. Subjects with both carotid artery stenosis and PAOD had a SAF of 3.28 (0.66) 
versus 2.66 (0.53) for subjects with only carotid artery stenosis without coexisting PAOD. 
When excluding patients with PAOD, the di"erence in SAF between the patients with 
carotid artery stenosis and controls was limited and even lost statistical signi!cance: 
SAF was 2.66 (0.53) versus 2.46 (0.57) with a p value of 0.08 (table II). Between the 
patients with carotid artery stenosis with and without coexisting PAOD no statistical 
di"erences between baseline characteristics could be found. Unlike PAOD, the presence 
of coexisting coronary artery disease did not result in a higher SAF. Subjects with carotid 
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artery stenosis and also coronary artery disease had a SAF of 2.82 (0.69) while this was 
2.81 (0.46) for patients with carotid artery disease without coexisting coronary disease.
Table II: Skin auto#uorescence in patients with carotid artery stenosis compared with healthy 
controls. 





Total group 2.81 (0.62) 56 2.46 (0.57) 56 0.002*
Total group without diabetes 2.75 (0.64) 44 2.46 (0.57) 56 0.016*
Total group with PAOD 3.28 (0.66) 14 2.46 (0.57) 56 0.000* 
Total group without PAOD 2.66 (0.53) 42 2.46 (0.57) 56 0.084
Total group with CAD 2.82 (0.46) 17 2.46 (0.57) 56 0.021*
Total group without CAD 2.81 (0.69) 39 2.46 (0.57) 56 0.008*
50-60 years 2.82 (0.54) 8 1.94 (0.30) 10 0.000*
50-60 years without diabetes 2.79 (0.37) 5 1.94 (0.30) 10 0.000*
60-70 years 2.73 (0.58) 23 2.40 (0.54) 21 0.06
70-80 years 2.90 (0.71) 21 2.73 (0.55) 24 0.37
>80 years 2.83 (0.74) 4 2.19 (n=1) 1 0.49
Analysis of di"erent age groups. Peripheral artery occlusive disease and coronary artery disease are denoted 
by respectively PAOD and CAD. Statistical signi!cance is notated by *.
Correlations and univariate analysis
Univariate analysis and correlations were performed in the combined total group to 
determine the relationship of di"erent parameters with SAF. A signi!cant correlation 
of SAF was found with age (r=0.29, p<0.01) and with renal function (r=0.24, p=0.01). 
A signi!cantly higher SAF was found in current smokers (mean 3.01 versus mean 2.47, 
p<0.001), diabetes mellitus (mean 3.03 versus 2.59, p=0.02), those using statins (mean 
2.87 versus 2.44, p<0.001), those with hypertension (mean 2.73 versus 2.48, p=0.04) 
and those with coexistence of PAOD (mean 3.28 versus 2.46, p<0.001). Gender, BMI, 
hypertension and coronary artery disease had no signi!cant in#uence in univariate 
analysis.
Backward linear regression analysis
Backward linear regression analysis was performed in the combined total group to 
determine the parameters that independently contributed to SAF. The results are shown 
in table III. Age, smoking, diabetes mellitus, renal function and presence of PAOD were 
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the signi!cant determinants of SAF. In contrast to the results of univariate analysis the 
presence of carotid artery disease did not contribute signi!cantly with a β of 0.074 
(p=0.83). Coronary artery disease also did not contribute with a β of 0.038 (p=0.48).
Table III: Results of backward linear regression analysis. 
Included parameter βeta p-value
Age 0.24 0.02
Current smoker 0.36 0.00
Diabetes mellitus 0.21 0.01
EGFR (MDRD) 0.20 0.05
Peripheral artery occlusive disease 0.29 0.00
The remaining signi!cant predictors of skin auto#uorescence are shown. Carotid artery disease, coronary 
artery disease, sex, BMI, hypertension and use of statin medication did not signi!cantly in#uenced skin 
auto#uorescence. Carotid artery disease and coronary artery disease both did not contribute signi!cantly with 
respectively a β of 0.074 (p=0.83) and 0.038 (p=0.48).
DISCUSSION
In the current study we showed that SAF is signi!cantly elevated in patients with 
carotid artery stenosis and PAOD compared to controls. Two !ndings were especially 
remarkable. 
 First, PAOD proved to be an important determinant of SAF. High SAF values were 
especially found in the group with carotid artery disease and coexisting PAOD. Even 
within the group of carotid artery disease, SAF was signi!cantly higher when there was 
coexisting PAOD with a SAF of 3.36 versus 2.64 (p=0.003). This could not be explained 
by di"erences in baseline characteristics between the patients with carotid artery 
stenosis with or without PAOD. Also in linear regression analysis, PAOD proved to be a 
strong determinant of SAF, even more so then diabetes. This !nding is interesting and 
warrants further research. It suggests that SAF should primarily be seen as an indicator 
of widespread atherosclerotic disease. Currently, a study analysing SAF in patients with 
primary peripheral artery disease has been initiated. 
 The second remarkable !nding was that SAF was speci!cally elevated for patients 
in the age group 50 to 60 years. Furthermore, the relation between age and SAF, as 
normally seen, was present in the control group but absent in the patients with carotid 
artery stenosis. 
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The marked elevation of SAF levels in carotid artery stenosis was demonstrated in 
non-diabetic patients as well as in diabetics. A high SAF in diabetes mellitus may 
therefore be regarded as an indicator of widespread atherosclerotic disease and not 
only a manifestation of diabetes mellitus per se. Mulder et al. previously reported 
similar !ndings in a cohort with stable coronary artery disease.15 SAF was signi!cantly 
increased in stable coronary artery disease compared with controls, irrespective of 
diabetes, current smoking and renal function. Earlier studies in patients with diabetes 
mellitus also showed that SAF is manifestly increased in these patients. The level of 
AGE accumulation correlated with the duration and the grade of complications of 
diabetes.2,3,21 
 Univariate and multivariate analysis of associations with SAF in the present study 
supports this interpretation in our study group of patients with carotid artery stenosis. 
SAF was univariately associated with age, smoking, diabetes mellitus, renal dysfunction, 
dyslipidaemia and the presence of carotid artery disease and peripheral arterial 
occlusive disease which is in concordance with earlier studies.2,3,11,14 Multivariately, SAF 
was determined by age, smoking, diabetes mellitus, renal dysfunction and peripheral 
arterial occlusive disease. Therefore, again, increased SAF may rather be regarded as an 
indicator of widespread atherosclerotic disease than as a speci!c identi!er of carotid 
atherosclerotic disease. 
 This study however has several limitations. At baseline, despite matching for sex 
and age in the control group, there were di"erences between the patient and control 
groups including presence of diabetes, smoking behaviour, hypertension, use of 
antihypertensive medication and use of statins. This may be considered a source of 
confounding. However, it does represent the expected increased presence of risk factors 
for cardiovascular disease in patients with carotid artery stenosis compared to healthy 
people.
 In the control group asymptomatic atherosclerosis may have existed as no carotid 
ultrasound or other vascular tests were performed in the control group. If asymptomatic 
atherosclerosis was present in the control group this would result in an underestimation 
of the di"erence between the control group and patient group. The di"erences we 
found between the control group and the group with atherosclerotic carotid stenosis 
and peripheral artery disease therefore would be even greater in a better selected 
control group. 
 Our study is also limited by the small number of patients. The fact that backward 
linear regression did not show carotid artery disease or coronary artery disease to 
be independent determinants of SAF may therefore be caused by the lack of power. 
Mulder et al has earlier shown that SAF indeed is elevated in stable coronary disease.15 
A large study evaluating the relationship between SAF en intima media thickness is 
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currently being executed to further clarify this issue. What may be the use of the present 
results? The correlation of SAF with traditional cardiovascular risk factors, the presence 
of diabetes, renal insu$ciency and peripheral arterial occlusive disease could indicate 
that SAF may be an indicator of high cardiovascular risk patients. Moreover, since SAF 
represents end organ damage it may predict morbidity and mortality more than the 
classical risk factors for atherosclerosis separately. For patients with type 2 diabetes this 
has already been established since SAF added prognostic information to the UKPDS risk 
calculator in predicting mortality.22 Strong predictive results of SAF for cardiovascular 
mortality were also seen in patients with renal failure.23 The same may be true for 
patients with carotid artery stenosis and peripheral artery disease. Prospective follow-
up studies are necessary to elucidate this. Moreover, spectroscopy techniques show 
promising results for imaging vulnerable plaques and the near future will tell whether 
they really shine light on unstable cardiovascular disease. 
 In conclusion, skin auto#uorescence is increased in patients with carotid artery 
stenosis and PAOD compared to healthy controls. SAF is especially elevated in the age 
group of 50 to 60 years, suggesting an increased accumulation of tissue AGEs in these 
patients. The univariate and multivariate associations of SAF with age, smoking, diabetes 
mellitus, presence of renal insu$ciency and peripheral arterial occlusive disease 
suggest that increased SAF should primarily be seen as an indicator of widespread 
atherosclerotic disease. These associations further underscore the important role of 
AGEs in the pathophysiology of atherosclerotic disease. SAF might therefore be an 
indicator of an overall high burden of widespread atherosclerosis as a consequence 
of AGE accumulation. Future research should investigate the use of SAF as a superior 
predictor of cardiovascular events in this population.
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Objective: Evidence for an important role of Advanced Glycation Endproducts (AGEs) 
in the development of atherosclerosis and cardiovascular disease beyond diabetes 
mellitus (DM) and renal disease is growing. Skin auto#uorescence (SAF) is a validated 
non-invasive measure of tissue AGEs. We hypothesized that SAF is elevated in peripheral 
artery disease (PAD).
Methods and Results: A case control study was performed in 492 patients with PAD and 
164 controls, matched for age (mean 66±10 years) and presence of DM. Cardiovascular 
risk factors and co-morbidity (coronary artery disease, cerebrovascular disease, 
abdominal aortic aneurysm (AAA)) were assessed. SAF was measured with the AGE 
ReaderTM. SAF was higher in patients compared to controls: geometric mean 2.77 (95% 
CI: 2.71-2.83) versus 2.44 (95% CI: 2.35-2.53) AU, p=0.4 x10-8. In logistic regression, the 
adjusted odds-ratio for presence of PAD was 2.47 (95% CI: 1.66-3.69) per 1 unit increase 
of SAF. PAD patients with cardiovascular co-morbidity had a higher SAF as compared to 
those without: geometric mean 2.93 (95% CI: 2.85-3.02) versus 2.63 (95% CI: 2.55-2.71) 
AU, p=0.4 x10-6, also after correction for confounders. Regression analysis showed that 
age, smoking, DM, chronic kidney disease and a history of cerebrovascular disease or 
AAA were independently associated with SAF in the PAD patients. 
Conclusion: Accumulation of tissue AGEs is increased in PAD patients, independent of 
cardiovascular risk factors and co-morbidity, although these conditions are associated 
with a further increase. These !ndings underscore the importance of AGEs in PAD, 
irrespective of the presence of diabetes and renal insu$ciency.




Patients with peripheral artery disease (PAD) are in#icted with a large burden of 
atherosclerosis, associated with a substantially increased risk for cardiovascular events 
and premature mortality.1-3 Advanced glycation endproducts (AGEs) are formed by non-
enzymatic glycation and oxidative reactions to form stable structures accumulating 
on long-lived proteins and promote cellular stress responses by engagement of the 
receptor for AGEs (RAGE).1 Although formerly only implicated in diabetes mellitus and 
renal disease, evidence for an important role of AGEs in cardiovascular disease beyond 
these conditions is growing. AGEs have been immunohistochemically localized in 
human atherosclerotic lesions and lowering AGEs or blocking AGE-receptors (RAGE) in 
murine models attenuates plaque formation, supporting a causal role of AGEs in the 
development of atherosclerosis.4-6 Indeed, in patients with peripheral artery disease 
(PAD), elevated levels of plasma AGEs have been documented.7 
 Skin auto#uorescence (SAF) is a validated measure of tissue AGEs that can be used 
in subjects with a skin pigmentation up to Fitzpatrick type V.8-10 Earlier, we reported that 
SAF was increased and a strong predictor of mortality in diabetes mellitus and end stage 
renal disease.9,11,12 The aim of the present study was to compare SAF in PAD patients with 
controls. We hypothesized that SAF is increased in PAD. Furthermore, we explored the 
relation of SAF with the traditional cardiovascular risk factors as well as with additional 
cardiovascular damage expressed by a history of cerebrovascular and/or coronary 
artery disease and/or an abdominal aortic aneurysm in these patients. 
METHODS
Study population
We performed a case-control study. Men and women at least 18 years of age were 
eligible to participate. PAD was ascertained by a resting ankle-brachial index (ABI) ≤0.90 
or a toe-brachial index ≤0.70 in case of noncompressible calf arteries. PAD was con!rmed 
by evidence of obstructive disease on computed tomographic angiography, magnetic 
resonance angiography, catheter angiography and/or duplex ultrasonography. An 
age-matched control group was selected from patients without a history of PAD that 
visited the outpatient clinic for pre-operative evaluation for orthopedic or minor 
surgical procedures. Since diabetes mellitus and end-stage renal disease strongly 
increase AGEs levels, PAD patients with diabetes mellitus were matched with diabetic 
controls and patients with end-stage renal disease (chronic kidney disease (CKD)13 stage 
5; estimated GFR<15 ml/min/1.73 m2) were excluded from both groups. Additional 
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exclusion criteria for patients and controls were recent myocardial infarction, stroke or 
sepsis (all within the past 3 months), cancer and solid organ transplantation. Patients 
and control subjects were not matched by gender, since no di"erence in SAF was found 
between men and women in previous studies.8,9,11,12 We designed the study to have 3:1 
matching (patients:controls) in order to have su$cient patients for additional analyses 
(see statistical analysis). For each set of three patients with approximately the same age 
(maximum deviation of 1 year from their mean age) one age-matched control subject 
was selected.
 The study was approved by the local institutional review board and all participating 
subjects gave informed consent. 
Evaluation
For data collection, history was taken and medical records were reviewed. Traditional 
cardiovascular risk factors were assessed: age, gender, smoking status, body mass index 
(BMI), diabetes mellitus, hypertension and hypercholesterolemia. BMI was calculated as 
weight (kilogram) divided by squared height (meters). Patients were classi!ed as having 
hypertension based on use of blood pressure lowering drugs and hypercholesterolemia 
was assigned in case of current use of lipids lowering drugs. The American Diabetes 
Association criteria were used to diagnose diabetes mellitus.14 Serum creatinine was 
determined and renal function was estimated by calculating the glomerular !ltration 
rate (eGFR).15 Renal insu$ciency was classi!ed according to CKD stage.13 Anticoagulant 
therapy was de!ned as the use of antiplatelet or vitamin K antagonist therapy. 
Coronary artery disease (CAD) was evaluated by clinical history of myocardial infarction, 
angina pectoris, coronary artery surgery and/or percutaneous coronary intervention. 
Cerebrovascular disease (CVD) was ascertained by history of symptoms of transient 
ischemic attack and/or stroke. An aneurysm of the abdominal aorta (AAA) was de!ned 
as a previously documented maximum infrarenal aortic diameter of ≥30 mm. For 
PAD patients without CAD, 10 year risk of a coronary event was estimated according 
to the Framingham risk score. This score is depending on age, total cholesterol, HDL-
cholesterol, systolic and diastolic blood pressure, presence of diabetes and smoking.16 
Patients were classi!ed into three risk categories depending on gender and Framingham 
risk score: low (<10%), intermediate (10 to 20%), or high (>20%) 10 year risk of having a 
coronary event. Since this score is validated for subjects <75 year, all patients ≥75 year 
were excluded for this calculation.
Skin auto!uorescence
SAF was measured with the AGE ReaderTM (DiagnOptics Technologies BV, Groningen, 
the Netherlands). The AGE Reader is a desk-top device that uses the characteristic 
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#uorescent properties of certain AGEs to estimate the level of AGEs accumulation in the 
skin. Technical details of this non-invasive device concerning the optical technique have 
been described more extensively elsewhere.8 In short, the AGE Reader illuminates a skin 
surface of 4 cm2 guarded against surrounding light with an excitation light source with a 
peak excitation of 370 nm (ultraviolet A). Emission light (#uorescence in the wavelength 
of 420-600 nm) and re#ected excitation light (with a wavelength of 300-420 nm) from the 
skin is measured with a spectrometer. SAF is calculated as the ratio between the emission 
light and re#ected excitation light, multiplied by 100 and expressed in arbitrary units 
(AU). In previous validation studies using skin biopsies, we showed a strong correlation 
between SAF and the skin contents of the #uorescent AGE pentosidine as well as with 
the non-#uorescent AGEs Nε-(carboxymethyl)-lysine (CML) and Nε-(carboxyethyl)lysine 
(CEL).8,9 Also, a strong correlation between SAF measurements of the arm and leg was 
found in a validation study. In the current study, the right forearm was positioned on top 
of the device which is the standard and most practical measuring site for SAF. A series of 
three consecutive measurements was carried out, taking less than a minute. The mean 
SAF was calculated from these three measurements and used in the analyses. An earlier 
validation study showed an intra individual Altman error percentage of 5.03% with SAF 
measurements taken over 1 single day and an Altman error percentage of 5.87% for 
seasonal variation.8
Statistical analysis
All data are shown as number (percentage) for categorical variables, as mean 
(± standard deviation) for variables with a normal distribution and as geometric mean 
(95% con!dence interval) in case of a non-normally distributed parameter that was 
normalized by logarithmic transformation. Normal distribution was tested by a one 
sample Kolmogorov-Smirnov test. Characteristics of patients and control subjects were 
compared by use of the χ2 test for categorical variables and Student independent t-test 
for continuous variables. SAF between patients and controls was compared by Student 
independent t-test. Within the group of PAD patients, the e"ect of the presence of each 
traditional cardiovascular risk factor, the presence of additional cardiovascular damage 
(expressed by a history CAD, CVD or AAA), and the e"ect of ABI and Framingham risk score 
category on SAF was tested in a univariate analysis by Student independent t-test or one-
way ANOVA where applicable. A p-value of <0.05 was considered statistically signi!cant. 
Backward linear regression was used to identify the independent determinants of SAF 
within the group of PAD patients. In the complete study group (patients and control 
subjects), logistic regression was performed to study the association between SAF and 
the presence of PAD. All statistical analyses were carried out with the Statistical Package 




Characteristics of patients and control subjects
Five-hundred and ten patients with PAD were willing to participate. Eighteen patients 
were excluded, 7 patients because of renal failure and 11 patients because of a kidney 
transplantation. The remaining 492 PAD patients and 164 control subjects, with a 
mean age of 66±10 years, were included. In 91 patients, PAD was not ascertained 
by a resting ABI ≤0.90 because of noncompressible arteries (33 patients) or because 
invasive angiography and/or surgery had directly been performed (58 patients). In 
all of these cases, PAD was con!rmed by angiography. The characteristics of patients 
and controls are shown in table I. These characteristics are shown for the complete 
group of PAD patients, as well as for the two subgroups of PAD patients with and 
without a history of cardiovascular co-morbidity (CAD, CVA and/or AAA). As expected, 
the traditional cardiovascular risk factors were more prevalent in the PAD patients 
than in the control subjects. Male gender, current smoking, hypertension and 
hypercholesterolemia were more common in the PAD patients (p≤0.001 for all). PAD 
patients had a slightly, but statistically signi!cant higher eGFR (77 (95% CI: 74-79) versus 
72 (95% CI: 69-75) ml/min/1.73 m2, p=0.02) and a lower BMI (p<0.001). Diastolic blood 
pressure was lower in PAD patients (p<0.01), probably due to the more frequent use of 
blood pressure lowering drugs. Obviously, PAD patients used oral anticoagulants more 
often (p<0.001). CAD and AAA were more prevalent in PAD patients (both p<0.001), but 
the prevalence of CVD did not di"er between PAD patients and control subjects.
Skin auto!uorescence
SAF was higher in PAD patients as compared to the control subjects: geometric mean 
2.77 (95% CI: 2.71-2.83) versus 2.44 (95% CI: 2.35-2.53) AU, (p=0.4x10-8), see !gure 1. 
The univariate in#uence of the presence of traditional risk factors, cardiovascular co-
morbidity and of the ABI on SAF is shown in !gure 2. Age, presence of diabetes mellitus, 
renal function and a history of CAD, CVD or AAA had a signi!cant e"ect on SAF. Gender, 
current smoking, presence of hypertension and of hypercholesterolemia, BMI and ABI 
were not correlated with SAF. The results of the multivariate linear regression analysis 
with SAF as dependent variable are shown in table II. Age, current smoking, diabetes 
mellitus, CKD class and a history of CVD or AAA were independently associated with 
SAF. The variables gender, hypertension, BMI, hypercholesterolemia, a history of CAD 
and ABI did not independently contribute to SAF.
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Table I: Baseline characteristics. 






N  Total group 164 492
No CV co-morbidity  252
With CV co-morbidity  240
Age in years  Total group 65.8 (10.4) 65.9 (10.5) N/A
No CV co-morbidity  63.0 (11,1)¶
With CV co-morbidity  68.8 (8,9)
Male gender  Total group 88 (54%) 345 (70%) 0.0001
No CV co-morbidity  155 (62%)¶
With CV co-morbidity  190 (79%)
Current smoker  Total group 37 (23%) 251 (51%) 0.2 x10-9
No CV co-morbidity  150 (60%)¶
With CV co-morbidity  101 (42%)
Body Mass Index in kg/m2 *  Total group 27.8 (27.1-28.5) 26.3 (25.9-26.7) 0.0002
No CV co-morbidity  25.8 (25.2-26.4) #
With CV co-morbidity  26.9 (26.4-27.4)
Diabetes mellitus  Total group 42 (26%) 127 (26%) N/A
No CV co-morbidity  54 (21%)**
With CV co-morbidity  73 (30%)
Systolic BP (mmHg) † Total group 149 (23) 146 (25) NS
No CV co-morbidity  147 (25)
With CV co-morbidity  145 (25)
Diastolic BP (mmHg) ‡  Total group 82 (11) 79 (14) 0.002
No CV co-morbidity  81 (15)**
With CV co-morbidity  78 (14)
Hypertension  Total group 67 (41%) 403 (82%) 0.5 x10-23
No CV co-morbidity  181 (72%)¶
With CV co-morbidity  222 (93%)
Hypercholesterolemia  Total group 48 (29%) 372 (76%) 0.9 x10-26
No CV co-morbidity  173 (69%)¶
With CV co-morbidity  199 (83%)
Oral anticoagulant therapy  Total group 53 (32%) 436 (89%) 0.1 x10-45
No CV co-morbidity  209 (83%)¶
With CV co-morbidity  227 (95%)
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eGFR (ml/min/1.73m2) §  Total group 72 (69-75) 77 (74-79) 0.02
No CV co-morbidity  83 (80-87)¶
With CV co-morbidity  71 (67-74)
Ankle-brachial index ||  Total group N/A 0.57 (0.14) N/A
No CV co-morbidity  0.57 (0.14)
With CV co-morbidity  0.57 (0.15)
Coronary artery disease 
(CAD)  Total group 23 (14%) 168 (34%) 0.9 x10-6
No CV co-morbidity  0 (0%)¶
With CV co-morbidity  168 (70%)
Cerebrovascular disease 
(CVD)  Total group 27 (17%) 76 (15%)
NS
No CV co-morbidity  0 (0%)¶
With CV co-morbidity  76 (32%)
Abdominal arterial aneurysm 
(AAA)  Total group 0 (0%) 61 (12%) 0.2 x10-5
No CV co-morbidity  0 (0%)¶
With CV co-morbidity  61 (25%)
Data presented as numbers of patients (%), mean (SD) or as geometric mean (95% CI). Cardiovascular (CV) 
co-morbidity de!ned as a history of CAD and/or CVA and/or AAA. eGFR=glomerular !ltration rate by MDRD 
formula. Patients and controls were matched on age and presence of diabetes mellitus. BP=blood pressure. 
NS=non-signi!cant. N/A=not applicable.
* Data missing for 1 control patients and 5 PAD patients, BMI was natural log transformed for analysis.
† Data missing for 1 control patients and 2 PAD patients.
‡ Data missing for 1 control patients and 4 PAD patients.
§ Data missing for 13 control patients and 6 PAD patients, eGFR was natural log transformed for analysis.
|| Data missing for 91 PAD patients.
PAD patients with versus without CV co-morbidity, ¶ p<0.001, # p<0.01, ** p-value<0.05.
Table I also shows the characteristics of PAD patients in two subgroups: patients 
with and without additional cardiovascular co-morbidity (history of CVD and/or CAD 
and/or AAA). Patients with a history of cardiovascular co-morbidity were older, more 
often male, less frequently smokers, had a higher BMI, more often diabetes mellitus, 
hypertension and/or hypercholesterolemia, used oral anticoagulant therapy more 
often, had a lower eGFR and a lower diastolic blood pressure as compared to PAD 
patients without cardiovascular co-morbidity. Systolic blood pressure and ABI did not 
di"er between these groups. Figure 3 (left panel) shows the in#uence of an increasing 
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burden of atherosclerosis on SAF, with a history of CVD and/or CAD and/or AAA as 
marker of additional atherosclerotic burden. There was a signi!cant di"erence in SAF 
between patients with PAD without cardiovascular co-morbidity and patients with 
PAD and cardiovascular co-morbidity: 2.63 (95% CI: 2.55-2.71) versus 2.93 (95% CI: 2.85-
3.02) AU, p=0.4 x10-6. The di"erence in SAF between control subjects and PAD patients 
without cardiovascular co-morbidity was signi!cant as well as with PAD patients with 
cardiovascular co-morbidity: 2.44 (95% CI: 2.35-2.53) versus 2.63 (95% CI: 2.55-2.71) AU, 
p=0.002 and 2.44 (95% CI: 2.35-2.53) versus 2.93 (95% CI: 2.85-3.02) AU, p=0.7 x 10-13 
respectively. After correction for gender and age, SAF remained signi!cantly di"erent 
between PAD patients with and without cardiovascular co-morbidity (p=0.0005) as well 
as between controls and PAD patients without cardiovascular co-morbidity (p=0.0001) 
and between controls and PAD patients with cardiovascular co-morbidity (p=0.1 x10-11). 
Figure 3 also shows the relation between Framingham risk score category and SAF (right 
panel) in PAD patients without CAD and <75 year of age. Patients with a high risk had a 
higher SAF as compared to patients with an intermediate or low risk: 3.03 (2.86-3.20) vs 
2.62 (2.51-2.73) and vs 2,54 (2.38-2.70), p=0.00006 and p=0.00005, respectively.
Figure 1: Skin auto#uorescence (SAF) in peripheral artery disease patients and control subjects. 




Table II: Multivariate model of (natural log of ) skin auto#uorescence in the peripheral artery 
disease patients: result of backward linear regression analysis.
Variable Coe&cient B Standard error Standardized  
coe&cient β
P-value
Age 0.005 0.001 0.227 0.000004
Smoking 0.097 0.022 0.195 0.00002
Diabetes Mellitus 0.113 0.024 0.204 0.000003
Natural log eGFR -0.061 0.030 -0.092 0.044
Cerebrovascular disease 0.073 0.029 0.109 0.011
Abdominal aortic aneurysm 0.070 0.032 0.095 0.028
Variables removed from the model: gender, natural log BMI, hypertension, hypercholesterolemia, coronary 
artery disease, ankle-brachial index.
eGRF = estimated glomerular !ltration.
Figure 2: Association of skin auto#uorescence (SAF) with cardiovascular risk factors (dichotomous 
variables are shown in panel A: smoking, gender, hypercholesterolemia, diabetes mellitus and 
hypertension; categorical variables are shown in panel B: age, CKD class and BMI class) and 
cardiovascular morbidity and ankle-brachial index (panel C: CAD, CVD, AAA and ankle-brachial 
index) in patients with peripheral artery disease (PAD). Data are shown as geometric mean (95% 
CI). 
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AU=arbitrary units. The gray area represents the geometric mean (95% CI) SAF of the control group. NS=not 
signi!cant. HC=hypercholesterolemia. DM=diabetes mellitus. Age category by decade, except for the lowest 
category consisting of all patients <50 years and the highest category consisting of all patients ≥80 years. CKD: 
chronic kidney disease classi!cation (see text). Patients without kidney disease are combined with patients in 
CKD 1. CKD data are missing for 6 PAD patients. BMI=Body mass index; class 1=underweight, BMI <18.5 kg/m2; 
class 2=normal weight, 18.5≤ BMI <25.0 kg/m2; class 3=overweight, 25.0 ≤ BMI <30 kg/m2; class 4=obesity, 
BMI ≥30 kg/m2. BMI data are missing for 5 PAD patients. CAD=coronary artery disease. CVD=cerebrovascular 
disease. AAA=abdominal aortic aneurysm. ABI=ankle-brachial index; NCA=group with noncompressible 
arteries, ID=group with directly invasively diagnosed PAD without ABI measuement.
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Table III: Logistic regression models for the association between peripheral artery disease 
(PAD) and skin auto#uorescence (SAF). 
Variable B Standard error Odds Ratio (95% CI)
Crude model
SAF 0.85 0.16 2.34 (1.73-3.17)
Constant -1.17 0.41 0.31
Model 1
SAF 0.86 0.20 2.36 (1.59-3.50)
Male gender 0.71 0.24 2.03 (1.26-3.26)
Smoking 1.45 0.28 4.25 (2.48-7.23)
Hypertension 1.56 0.27 4.78 (2.82-8.09)
Hypercholesterolemia 1.64 0.25 5.13 (3.12-8.43)
BMI -0.09 0.03 0.91 (0.87-0.96)
eGFR 0.01 0.01 1.01 (1.00-1.02)
Constant -2.95 1.09 0.05
Model 2
SAF 0.82 0.16 2.27 (1.66-3.09)
CVD -0.40 0.26 0.67 (0.40-1.12)
CAD 1.08 0.25 2.95 (1.81-4.80)
Constant -1.27 0.42 0.28
Model 3
SAF 0.91 0.20 2.47 (1.66-3.69)
Male gender 0.73 0.25 2.07 (1.26-3.37)
Smoking 1.47 0.28 4.35 ( 2.53-7.47)
Hypertension 1.58 0.28 4.85 (2.80-8.39)
Hypercholesterolemia 1.66 0.27 5.28 (3.12-8.92)
BMI -0.09 0.03 0.91 (0.86-0.95)
eGFR 0.01 0.01 1.01 (1.00-1.02)
CVD -1.07 0.33 0.34 (0.18-0.65)
CAD 0.39 0.32 1.48 (1.80-2.75)
Constant -2.85 1.10 0.06
eGFR=estimated glomerular !ltration rate by MDRD formula. BMI=body mass index. CVD=cerebrovascular 
disease, CAD=coronary artery disease. Since PAD patients and controls were matched for age and presence 
of diabetes mellitus, these variables were not included in the model. For gender, female is the reference. AAA 
was excluded from the model; no estimation of the odds ratio is possible since there are no control subjects 
with an AAA.
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Table III shows the results of the logistic regression models that describe the 
association between SAF and the presence of PAD in the complete group (patients 
and controls). In the crude model, each 1 AU increase of SAF was associated with 
a 2.34 fold (95% CI: 1.73-3.17) increased chance of having PAD. The strength of this 
association was una"ected by correction for cardiovascular risk factors (model 1, OR 
2.36 (95% CI: 1.56-3.50)), history of CAD and CVD (model 2, OR 2.27 (95% CI: 1.66-3.09)) 
and cardiovascular risk factors and history CAD and CVD (model 3, OR 2.47 (95% CI: 
1.66-3.69)).
Figure 3: Data are shown as geometric mean and 95% con!dence interval (CI). 
AU=arbitrary units. NS=not signi!cant. Left panel: skin auto#uorescence (SAF) in peripheral artery disease (PAD) 
patients with and without cardiovascular co-morbidity (cardiovascular and/or cerebrovascular disease and/
or abdominal aortic aneurysm) and control subjects (PAD-). PAD/+CV–=PAD patients without cardiovascular 
co-morbidity. PAD+/CV+=PAD patients with cardiovascular co-morbidity. Right panel: SAF in PAD patients 
without coronary artery disease (n=324) with a low (<10%), intermediate (10 to 20%), or high (>20%) 10 year 
risk of a coronary event according to the Framingham risk score (FRS). FRS could be calculated for 236 patients. 





Our study in patients with PAD shows that SAF, as a measure of tissue AGEs accumulation, 
is considerably increased compared to control subjects, independent of cardiovascular 
risk factors and cardiovascular co-morbidity. Still, the presence of cardiovascular risk 
factors known to be strongly associated with PAD further increases SAF in PAD patients. 
Multivariate analysis shows that age, current smoking, presence of diabetes mellitus, 
eGFR and a history of CVD or AAA are independent determinants of SAF in patients 
with PAD. This is in agreement with our previous studies. Furthermore, a 1 unit increase 
in SAF is associated with a 2.45 fold higher chance of having PAD, independent of 
cardiovascular risk factors and cardiovascular co-morbidity in the complete group.
Advanced glycation end products in PAD
This is the !rst report demonstrating an increased SAF in PAD patients, although we 
earlier reported that increased SAF in patients with carotid artery disease was con!ned 
to those with PAD.17 The role of AGEs in the pathogenesis of PAD has recently been 
suggested, which is in line with the more established concept of AGEs as important 
players in the development of atherosclerosis in diabetes mellitus, renal insu$ciency 
and coronary artery disease.9,11,12,18
 The literature on AGEs in PAD, however, is relatively scarce. Previously, in a study of 
patients with end stage renal disease, plasma levels of S100A12, which is a ligand for the 
receptor for AGEs (RAGE), where elevated in the patients with PAD as compared to those 
without PAD.19 Furthermore, a direct inverse association between ABI and circulating 
levels of the AGE pentosidine was found in apparently healthy men.20 However, no 
patients with documented PAD or an ABI below 0.9 were included. In contrast, we 
included PAD patients with a mean ABI of 0.57 and did not !nd any relation between 
SAF and ABI in the univariate analysis. Also the multivariate model showed that in our 
PAD patients, SAF was primarily depending on age, smoking, DM and renal function 
rather than the severity of PAD as assessed by the ABI. Interestingly, we did !nd that 
SAF was particularly increased in those PAD patients that had additional cardiovascular 
morbidity, univariately as well as in the multivariate model. Therefore, in these patients, 
AGEs may re#ect the burden of atherosclerosis with incremental AGEs accumulation 
in those patients in whom atherosclerosis is not con!ned to the peripheral arteries 
but extends to the aorta, coronary or cerebral arteries as well. In line with this concept 
of increasing AGEs with increased manifestation of atherosclerosis are the results 
of a postmortem study in patients with diabetes mellitus demonstrating a stronger 
expression of RAGE in patients with an increased necrotic plaque area in the coronary 
arteries.21
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In our study, logistic regression analysis showed that each 1 AU increase of SAF was 
associated with a 2.34 fold increased chance of having PAD in the crude model. The 
independency of SAF as a determinant of the presence of PAD was underscored by the 
unchanged strength of their association in models that include an increasing number 
of known determinants of the presence of PAD such as smoking, hypertension and the 
presence of CAD. The main outcome of our study that shows an increased SAF in PAD 
as well as the additional analyses further reinforce the concept of a key role for AGEs in 
development of atherosclerotic disease, in particular PAD.
Limitations of the study
The selection of PAD patients and controls may have in#uenced the results. The controls 
were not selected on being healthy, but only on being free of symptoms or signs of PAD. 
However, if there have been control patients with PAD at a subclinical level, this has 
resulted in an underestimation rather than an overestimation of the true di"erence in 
SAF between patients with PAD and control subjects. Furthermore, patients and controls 
were matched for age and the presence of diabetes mellitus, because in earlier studies 
these were the most important determinants of SAF.8,9,11,12,17,18 This, again, may have lead 
to an underestimation of the true di"erence in SAF between PAD and controls. The same 
is true for the exclusion of patients with end stage renal disease (CKD class 5, on dialysis, 
of after kidney transplantation). We had to exclude 18 patients and none of the control 
subjects because of this criterion, while end stage renal disease is known to impair 
clearance of AGEs resulting in accelerated accumulation of AGEs. 
 Generalisability of the results may be limited to a part of all PAD patients. The low 
mean ABI of 0.57 demonstrates that our group of PAD patients su"ered from severe 
PAD, especially when taking into account that the ABI was not measured in 58 patients 
because invasive angiography and/or surgery had directly been performed, necessitated 
by the clinical presentation of these patients with critical ischemia. The high prevalence 
of most cardiovascular risk factors in the PAD patients of our study may be expected 
in a cohort with established vascular disease. The high percentages of patients with 
hypertension or hypercholesterolemia in the patients with PAD can be explained by 
the fact that these conditions are known risk factors for PAD, but also by the de!nition 
we used for these conditions i.e. the use of antihypertensive or cholesterol lowering 
drugs. These drugs may have been prescribed as secondary cardiovascular prevention 
measures rather than because of the presence of hypertension or hypercholesterolemia.
 Also, we did not perform skin biopsies in the present study to con!rm the strong 
correlation between SAF and skin content of AGEs, as reported in earlier validation 
studies in di"erent patient groups and healthy controls.8,9 Furthermore, we did not 
measure plasma AGEs to corroborate our !ndings. However, it is unclear whether 
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sampling of plasma AGES would have been useful, since blood and urine sampling of 
AGEs is hampered by the fact that these AGEs not necessarily re#ect tissue AGE levels.22,23
 A major limitation of the use of skin auto#uorescence by the AGE reader to measure 
AGEs level is that it cannot be used in all types of skin. For a valid measurement of skin 
auto#uorescence the re#ectance of excitation light has to be at least 6%.10 Strongly 
pigmented skin type absorbs too much excitation light, resulting in a re#ectance of less 
than 6%. In practice, the AGE reader can be used subjects with a skin pigmentation 
up to Fitzpatrick skin type V. Therefore, the AGE reader can be used in subjects with a 
Caucasian, Mediterranean, Hispanic, Asian or Eastern Indian or origin, but not in African 
Americans.
 Finally, we do not know the strength of the correlation between SAF and actual level 
of AGEs in the atheroma of a"ected arteries. A study on the agreement between SAF 
as measure of tissue AGEs in the skin and tissue AGEs or plaque size in arteries has yet 
to be performed. Still, in patients with type 1 diabetes mellitus, another research group 
has established the positive association between coronary artery calci!cation score and 
skin intrinsic #uorescence (SIF) measurements that in essence use the same #uorescent 
properties of AGEs in the skin as the AGE reader we used.24 Also, a recently published 
study showed a correlation between SAF and the actual content of AGEs in residual 
bypass graft material.25 SAF as a non-invasive method to quantify tissue accumulation 
of AGEs has made it possible to study 656 subjects in the present study relatively easily, 
not needing skin biopsies or atheroma of a"ected arteries. 
Clinical implications
Notwithstanding these limitations, our observation of highly increased SAF in PAD 
patients remains relevant, while the use of SAF as a measure of tissue AGEs deposition 
has been validated earlier and used as such in a series of prospective clinical studies 
as well.8 In several of these studies SAF was shown to be a strong predictor for 
cardiovascular morbidity and mortality and total mortality, independent of conventional 
cardiovascular risk factors.9,11,12,17,18 If such a predictive value can be established in PAD 
patients, SAF may be used to identify PAD patients at highest risk for cardiovascular 
events. Our observation of a relation between SAF and Framingham risk score category 
supports the possibility of the use of SAF for risk prediction in PAD patients. However, 
this has yet to be shown in a prospective follow-up study. Likewise, whether PAD 
patients with a high SAF may bene!t from more aggressive treatment (i.e. tighter control 
of cardiovascular risk factors with lower LDL-cholesterol and blood pressure targets), 
similar to patients with diabetes mellitus or renal insu$ciency, should be subject to an 
intervention study. Finally, inhibition of AGE formation, breakdown of AGE-crosslinks 
and blocking the receptor for AGEs may become treatment targets in cardiovascular 
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disease. Drugs that are currently prescribed to treat diabetes mellitus, hypertension and 
hypercholesterolemia may have such properties to a certain extent, but also new drugs 
have speci!cally been designed to counter AGEs.26 However, although some of these 
new drugs have already been tested in clinical studies, e$cacy and safety concerns have 
prevented these drugs from their use in clinical practice.
Conclusions
Skin auto#uorescence, as a measure of tissue advanced glycation endproducts 
deposition, is considerably increased in patients with PAD as compared to controls. This 
increase is independent of the presence of cardiovascular risk factors or other established 
cardiovascular disease although these conditions are associated with a further increase 
of SAF. These !ndings underscore the importance of AGEs in PAD, irrespective of the 
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Aims: Skin auto#uorescence is a non-invasive marker of advanced glycation end 
product accumulation. In a previous study, skin auto#uorescence correlated with and 
predicted micro- and macrovascular complications in Type 2 diabetes in a primary care 
setting. The present cross-sectional study aims to con!rm the association between skin 
auto#uorescence and diabetic complications in patients with Type 2 diabetes in a multi-
centre secondary care setting.
Methods: We analysed 563 subjects with Type  2 diabetes mellitus from !ve Dutch 
hospitals.
Results: Median age was 64  years, median duration of diabetes 13  years and 
median HbA1c 58 mmol/mol (7.5%). Sixty-one per cent of patients had microvascular 
complications (38% nephropathy, 36% retinopathy, 35% neuropathy) and 42% had 
macrovascular complications. Median UK Prospective Diabetes Study 10-year risk 
for coronary events was 19%. Median skin auto#uorescence was elevated compared 
with age-matched healthy control subjects: 2.77 (interquartile range 2.39-3.28) vs. 
2.46 (2.08–2.84) arbitrary units. Skin auto#uorescence was particularly increased in 
patients with complications: no complications, median 2.56 (2.26-2.90); microvascular 
complications, 2.79 (2.38-3.29); macrovascular complications, 2.85 (2.41-3.41); both 
micro- and macrovascular complications, 2.96 (2.56-3.60) arbitrary units,  P<0.001. 
Logistic regression analysis showed that age, duration of diabetes, renal function, 
gender, atrial !brillation and skin auto#uorescence were independently associated with 
macrovascular complications. Multiple regression analysis identi!ed age, smoking, renal 
function, macrovascular complications and the number of microvascular complications 
as the determinants of skin auto#uorescence.
Conclusions: This study con!rms that skin auto#uorescence is increased in patients 
with Type 2 diabetes in a secondary care setting. Skin auto#uorescence was associated 
with macrovascular complications in patients with diabetes and this association was 
independent of classical risk factors.




Advanced glycation end products accumulate in tissues with a low turnover during a 
lifetime.1,2 This is regarded as a process of normal ageing. The accumulation of accelerated 
advanced glycation end products results from combinations of hyperglycaemia, 
hyperlipaemia, oxidative/carbonyl stress and also decreased renal clearance of advanced 
glycation end product precursors.1,2 Highly accelerated advanced glycation end product 
formation and accumulation is seen in diabetes mellitus.1 This is considered one of the 
important pathogenetic mechanisms causing end organ damage in diabetes.1 Cross-
linking of proteins by advanced glycation end products and receptor-mediated cellular 
activation contribute to loss of elasticity of the vascular wall and to cellular in#ammation, 
resulting in micro- and macrovascular complications.1,3 The contents of the advanced 
glycation end products in skin biopsies predicted long-term diabetic complications in a 
large cohort of patients with Type 1 diabetes, even after adjustment for HbA1c.4,5
 Skin auto#uorescence has a strong correlation with the speci!c advanced glycation 
end product content in skin biopsies, as shown by multiple validation studies.6-8 Not only 
#uorescent advanced glycation end products (pentosidine), but also non-#uorescent 
advanced glycation end products such as N-carboxymethyl-lysine and N-carboxyethyl-
lysine in the skin biopsies correlated with skin auto#uorescence.6 We therefore consider 
skin auto#uorescence a non-invasive marker of tissue accumulation of advanced 
glycation end products. Earlier studies showed that skin auto#uorescence is increased 
in Type  2 diabetes compared with healthy control subjects.9 Skin auto#uorescence 
showed a strong association with the severity of diabetes-related complications.9,10 
Furthermore, it also predicted both micro- and macrovascular complications in patients 
with Type 2 diabetes.10 In a previous prospective follow-up study, skin auto#uorescence 
had an additional value to the UK Prospective Diabetes Study (UKPDS) risk score for 
estimating mortality in Type  2 diabetes mellitus.11 However, these !ndings concern 
one single-centre cohort of well-controlled patients with Type 2 diabetes in a primary 
care setting. Our study aims to con!rm the relation between skin auto#uorescence 
and diabetic complications and possibly broaden our insight into the role of skin 
auto#uorescence in predicting micro- and macrovascular complications. We evaluated 
skin auto#uorescence in a group of patients with Type 2 diabetes in a secondary medical 
care setting. Furthermore, we chose a multi-centre approach to possibly support the 
generalizibility wider use of the results. Here, we present the baseline cross-sectional 
data. Prospective follow-up data on the predictive value of skin auto#uorescence on 





We recruited 616 subjects with Type 2 diabetes mellitus from !ve hospitals in di"erent 
regions of the Netherlands. The University Medical Centre Groningen (UMCG), Medical 
Centre Leeuwarden, Onze Lieve Vrouwe Gasthuis Amsterdam, Sint Franciscus Gasthuis 
Rotterdam and Het Diakonessenhuis Meppel participated in this study. Patients were 
included from April 2007 to November 2009. Informed consent was obtained from all 
participants. The study was approved by the Medical Ethical Committee.
Assessment of skin auto!uorescence
Skin auto#uorescence was measured with the advanced glycation end product (AGE) 
Reader™ (DiagnOptics Technologies BV, Groningen, the Netherlands). The AGE Reader is 
a desktop device that uses the characteristic #uorescent properties of some advanced 
glycation end products to estimate the level of advanced glycation end product 
accumulation in the skin. Technical and optical details of this non-invasive method have 
been described more extensively elsewhere.8 In short, the AGE Reader illuminates a 
skin surface of 4 cm2, guarded against surrounding light, with an excitation light source 
with a peak excitation of 370 nm. This wavelength is in the UVA spectrum. Emission 
light in the wavelength range of 420-600 nm (#uorescence) and excitation light that is 
re#ected by the skin with a wavelength range of 300-420 nm from the skin is measured 
with a spectrometer. Skin auto#uorescence was determined from the ratio between 
the emission light and the re#ected excitation light, using the AGE Reader software, 
version  2.2. Each participating medical centre was equipped with an AGE Reader 
and given user instructions for skin auto#uorescence measurement. Measurements 
were performed by a diabetes nurse or research assistant. Skin auto#uorescence was 
measured at room temperature while patients were at rest in a seated position. In the 
current series of experiments, the forearm was positioned on top of the device in the 
usual manner, as described by the manufacturer. Measurements were not speci!cally 
performed in a fasting state. For each skin auto#uorescence value, three consecutive 
measurements were carried out at three di"erent skin sites of the same forearm, 
within a total test period of approximately 2 min. The mean of these three consecutive 
measurements was used in the analyses. Skin pigmentation in#uences the measurement 
of skin auto#uorescence and its in#uence has been extensively studied and reported 
earlier.12 For a reliable skin auto#uorescence measurement, skin re#ectance had to be 
above 12% with the hardware and software (version 2.1) of the AGE Reader that was 
used. Patients with a dark-coloured skin with a re#ectance below 12% were excluded 
from the analysis.




Clinical data from the participating subjects were gathered from the electronic medical 
data system of the di"erent hospitals. Data on age, gender, diabetes duration, blood 
pressure and macrovascular events were collected from the medical records. HbA1c, a 
fasting lipid pro!le, serum creatinine and urinary microalbumin were received from the 
laboratories. The standard creatinine assays of the individual hospitals laboratories were 
used and they were all well standardized with validated assays. Glomerular !ltration rate 
(GFR) was estimated by the abbreviated Modi!cation of Diet in Renal Disease (MDRD) 
equation: 186 x (creatinine/88.4)−1.154 × (age)−0.203 × (0.742 if female) × (1.210 if black). The 
standard stages of chronic kidney disease (1–5) were used to classify renal insu$ciency. 
Diabetic nephropathy was scored as an albumin:creatinine ratio >3.5 in women and 
>2.5 in men on two successive samples, or at least once in the previous year while using 
an angiotensin-converting enzyme (ACE) inhibitor. Diabetic retinopathy was scored 
according to the report of the yearly evaluation by the patient’s ophthalmologist with 
retinal photography or fundoscopy. Diabetic neuropathy was scored by testing with 
a 5.07 Semmes-Weinstein mono!lament applied 10 times on three areas of each foot 
in a random order. An absent sensation of the mono!lament of three or more times 
(i.e. a score of lower than 8 of 10) was considered neuropathy. Microvascular disease 
was de!ned by either the presence of microalbuminuria and/or retinopathy (at least 
background retinopathy) and/or neuropathy. The presence of macrovascular disease was 
de!ned as a known history of coronary disease, cerebrovascular disease or peripheral 
vascular disease. Cardiovascular disease was de!ned as a history of ischaemic heart 
disease [International Classi!cation of Diseases (ICD) codes I20-25] and/or a history 
of percutaneous coronary intervention or coronary bypass surgery. Cerebrovascular 
disease was de!ned as a history of an ischaemic cerebrovascular accident (ICD codes 63-
64). Peripheral vascular disease was de!ned as a history of claudication with abnormal 
ankle-arm index (<0.8 on a single measurement or <0.9 on repeated measurements) 
or a history of surgical intervention of peripheral artery disease. Future cardiovascular 
risk of the individual patient was calculated by the UKPDS risk score. The following 
variables are used for risk calculation: age, duration of diabetes, gender, atrial !brillation, 
ethnicity, smoking behaviour, HbA1c, systolic blood pressure, total cholesterol and HDL 
cholesterol These provided a measure of the 10-year risk of fatal and non-fatal coronary 
and cerebrovascular events for each patient. As the UKDPS score incorporates these 10 
cardiovascular risk factors, we used the UKPDS score as a measure of cardiovascular risk.
Statistical analysis
We calculated sample size with a power of 80%, α=0.05. We adopted the standard 
deviation of 0.5 from the literature.13 We wanted to be able to demonstrate a di"erence 
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in skin auto#uorescence of 0.2  arbitrary units between groups with no diabetic 
complications, microvascular complications, macrovascular complications and 
combined micro- and macrovascular complications. Power analysis showed that 77 
subjects were needed in each group. Data were gathered in a database (SPSS 15-0; SPSS 
Inc., Chicago, IL, USA). Normal distribution of variables was assessed by Kolmorgorov-
Smirnov tests. Descriptive statistics are presented as mean with standard deviation in the 
case of normal distribution, otherwise as median with interquartile range or as number 
of patients. A paired Student  t-test was used for normally distributed variables and a 
paired Mann-Whitney U-test was used for variables with a skewed distribution. Multiple 
linear regression analysis was used to determine independent relations between skin 
auto#uorescence and clinical data, including age, duration of diabetes, gender, atrial 
!brillation, ethnicity, smoking behaviour, HbA1c, systolic blood pressure, cholesterol 
and the presence of micro- and macrovascular complications. Logistic regression 
analysis was used to determine which variables determined presence of macro- and 
microvascular disease. Analysis of variance (ANOVA) was applied to compare di"erences 
between groups. For cross tabulation, χ2 analysis was used.
RESULTS
Subject characteristics
A total of 616 patients were measured. Skin auto#uorescence measurements proved 
to be unreliable with the software version used in this study in 53 patients, mainly 
because of low re#ectance caused by dark pigmented skin. Therefore, 563 patients with 
Type 2 diabetes were included in our analysis. Baseline characteristics are presented 
in  Table  1. The median diabetes duration was 13  years and glycaemic control was 
suboptimal. Blood pressure and cholesterol were reasonably well controlled. A number 
of 126 patients (24%) had renal insu$ciency with a chronic kidney disease stage 3 or 
more. As expected, the number of subjects with diabetic complications was high in 
this secondary medical care setting: 61% had microvascular complications and 42% 
macrovascular complications.
Skin auto!uorescence
Skin auto#uorescence values for the total group and di"erent subgroups are given 
in  Table  2. Median skin auto#uorescence was 2.77 with an interquartile range of 
2.39-3.28 for the total group. This is elevated and, speci!cally, in the 79th percentile 
compared with reference values in healthy control subjects, where for this median 
age a median skin auto#uorescence of 2.46 (interquartile range 2.08-2.84) would be 
SAF and risk of micro- and macrovascular complications
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Table I: Baseline characteristics presented as mean (standard deviation), median (interquartile 
range) or as number of patients (%). 
Characteristic T2DM
Age (years) 64 (11.3)
Male sex 269 (47.9%)
Caucasian 517 (91.3%)
Atrial !brillation 41 (7.3%)
Current smoker 97 (17%)
Diabetes duration (years) 13.0 (7-19) 
HbA1c (mmol/mol, %) 58 (51-67), 7.5%
Systolic blood pressure (mmHg) 140 (130-150)
Total cholesterol (mmol/l) 4.2 (3.6-4.9)
HDL cholesterol (mmol/l) 1.2 (1.0-1.4)
GFR (ml/min) 75 (61-92)
CKD 
 none 83 (16%)
 stage 1 57 (11%)
 stage 2 253 (49%)
 stage 3 117 (22.5%)
 stage 4 9 (2%)
 stage 5 0
Diabetic nephropathy 195 (38%)
Diabetic retinopathy 189 (36%)
Diabetic neuropathy 161 (35%)
Microvascular disease 346 (61%)
Coronary artery disease 169 (30%)
Cerebrovascular disease 74 (13%)
Peripheral artery disease 85 (15%)
Total macrovascular disease 238 (42%)
Risk coronary events UKPD 19% (12-30)
Risk cerebrovascular events UKDPS 13% (6-29%)
expected.13 Table 2 shows that skin auto#uorescence slowly rises with increasing age, 
which is regarded as a physiological phenomenon of ageing.13 Skin auto#uorescence 
levels increased signi!cantly with increasing diabetic complications (P<0.001). 
In subjects without any diabetic complications, median skin auto#uorescence 
was 2.56 (interquartile range 2.26-2.90), which is the 65th percentile for healthy 
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control subjects of the same age. With microvascular complications, median skin 
auto#uorescence was 2.79 (interquartile range 2.38-3.29 and 80th percentile). In a 
univariate analysis, no di"erences in skin auto#uorescence values were found between 
patients with one, two or three microvascular complications (ANOVA,  P=0.12). With 
macrovascular complications, median skin auto#uorescence was 2.85 (interquartile 
range 2.41-3.41 and 82th percentile) and, in those with both micro- and macrovascular 
complications, median skin auto#uorescence was 2.96 (interquartile range 2.56-3.60, 
88th percentile). The di"erences in skin auto#uorescence between patients without 
diabetic complications, with microvascular complications and with both micro- and 
macrovascular complications remained signi!cant after correction for age (P=0.008).
 
Table II: Skin auto#uorescence according to microvascular and macrovascular complications 
and in di"erent age groups (median with interquartile range).
Skin auto!uorescence  N
Total group of T2DM 2.77 (2.39-3.28) 563
T2DM without any complications 2.56 (2.26-2.90) 141
T2DM with microvascular complications 2.79 (2.38-3.29) 181
T2DM with macrovascular complications 2.85 (2.41-3.41) 71
Both micro- and macrovascular 
complications
2.96 (2.56-3.60) 169
<50 years 2.37 (2.00-2.76) 55
50-60 years 2.63 (2.30-3.03) 120
60-70 years 2.77 (2.36-3.20) 195
70-80 years 3.08 (2.61-3.50) 142
>80 years 3.09 (2.57-3.87) 51
Association between skin auto!uorescence, micro- and macrovascular 
complications
Multiple linear regression analysis was performed to evaluate which variables were 
associated with skin auto#uorescence. Up to 19% in the variance of skin auto#uorescence 
could be explained by age (β=0.28, P<0.000), smoking (β=0.18, P<0.000), renal function 
(eGFR) (β=-0.13, P<0.006), macrovascular complications (β=0.11, P=0.009) and number 
of microvascular complications (β=0.081,P=0.045). Medical centre, gender, duration of 
diabetes, HbA1c, systolic blood pressure and lipid pro!le did not signi!cantly in#uence 
skin auto#uorescence. When we entered nephropathy, neuropathy and retinopathy 
separately in the regression analysis, none of them were signi!cant.
SAF and risk of micro- and macrovascular complications
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Subsequently, we analysed which variables were associated with the presence 
of macrovascular disease. Logistic regression analysis showed age (odds ratio 
1.03, P=0.05), renal function (eGFR) (odds ratio 0.98, P=0.008), diabetes duration (odds 
ratio 1.03,  P=0.01), gender (odds ratio 0.51,  P=0.001), atrial !brillation (odds ratio 
0.39, P=0.02) and skin auto#uorescence (odds ratio 1.45, P=0.023) to be independently 
associated with the presence of macrovascular disease. Medical centre, HbA1c, lipid 
pro!le, smoking, systolic blood pressure and microvascular disease, however, were not 
independently associated with the presence of macrovascular disease.
 Predictors of the presence of microvascular disease were duration of diabetes 
(odds ratio 1.05,  P=0.002), renal function (eGFR) (odds ratio 0.98,  P<0.000) and skin 
auto#uorescence (odds ratio 1.60, P=0.004). HbA1c, age, gender, smoking, systolic blood 
pressure and lipid pro!le did not contribute signi!cantly.
Table III: Percentage of macrovascular complications according to di"erent tertiles SAF and 




1rst 2nd 3rd total
Tertiles 1rst 20.2 27.9 37.8 26.2
UKPDS 2nd 35.6 34.9 50.7 40.7
risk score 3rd 51.3 56.9 66.3 59.9
total 31.6 40.2 55.1
Macrovascular diabetic complications by UKPDS risk score and skin 
auto!uorescence
Regression analysis showed that skin auto#uorescence was independently associated 
with the presence of macrovascular complications. Subsequently, we divided the 
patients into tertiles of UKPDS risk score and tertiles of skin auto#uorescence. In these 
cross-sectional data, we used the UKPDS risk score as a measure of cardiovascular risk, 
integrating classical cardiovascular risk factors and glycaemic control. For the di"erent 
tertiles, we analysed the prevalence of macrovascular complications. Results are shown 
in Table 3. Within each tertile of skin auto#uorescence, the prevalence of macrovascular 
complications increased signi!cantly. Macrovascular complications rose from 32% in 
the 1st skin auto#uorescence tertile to 55% in the 3rd tertile (P<0.000). For the tertiles 
according to UKPDS risk score, the same phenomenon was seen: with each tertile, 
macrovascular complications were signi!cantly higher (P<0.000). Interestingly, within 
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each tertile of UKPDS risk score, skin auto#uorescence appeared to further determine 
the presence of macrovascular complications. When focusing on the 1st UKPDS tertile, 
macrovascular complications were present in 20% in the 1st skin auto#uorescence 
tertile, while this was 38% in the 3rd skin auto#uorescence tertile (P=0.04).
DISCUSSION
Skin auto#uorescence was previously shown to predict micro- and macrovascular 
complications in one prospective study in a single-centre cohort of well-controlled 
patients with Type  2 diabetes in the primary care setting.9,10 In this cohort, skin 
auto#uorescence even proved to add predictive information on cardiovascular 
prognosis to the UKPDS risk score.11
 Our present multi-centre study in the secondary medical setting con!rms that 
skin auto#uorescence is indeed increased in patients with Type  2 diabetes mellitus. 
Furthermore, it con!rms that skin auto#uorescence levels have a graded relation with 
the presence of micro- and macrovascular complications. Our cohort had a relatively 
long duration of diabetes of 13 years and a reasonable, although not optimal, glycaemic 
control. The prevalence of micro- and macrovascular diabetic complications, as well 
as UKPDS risk score, were somewhat higher, but not much di"erent than previously 
described in studies concerning skin auto#uorescence in Type 2 diabetes mellitus.9-11 
The cohort we describe is surprisingly similar to the cohort in the primary care setting 
that Lutgers and co-workers previously presented.9-11 Age, sex, smoking behaviour, 
creatinine clearance, micro- and macrovascular disease and skin auto#uorescence 
values were similar in both populations. Our cohort had a longer diabetes duration 
(13 vs. 4 years), a marginally higher HbA1c [58 vs. 53 mmol/mol (7.5 vs. 7.0%)], a better 
controlled systolic blood pressure (140 vs. 146  mmHg) and better controlled total 
cholesterol (4.2 vs. 5.2 mmol/l).
 In our study, we show that skin auto#uorescence was independently associated 
with the presence of both micro- and macrovascular complications. Surprisingly, 
most classical cardiovascular risk factors and glycaemic control were not signi!cantly 
associated with the presence of macrovascular disease. Macrovascular disease was 
predicted by age, diabetes duration, renal function (eGFR), gender, atrial !brillation 
and skin auto#uorescence. Speci!cally, HbA1c, blood pressure and lipid pro!le did not 
contribute. Earlier studies showed that HbA1c and skin auto#uorescence have a limited 
relation,14 suggesting that skin auto#uorescence is only partly determined by the 
components of the slow Maillard reaction.
SAF and risk of micro- and macrovascular complications
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When, in our present cohort, the UKPDS risk score and skin auto#uorescence were both 
divided into tertiles, there was an increasing percentage of patients with macrovascular 
complications within each tertile of UKPDS risk score (as an integration of the classical 
risk factors and glycaemic control), going from the 1st to the 3rd skin auto#uorescence 
tertile. The association between prevalence of macrovascular complications, UKPDS 
risk score and skin auto#uorescence, which we present now on cross-sectional data, 
has no value in prediction of future cardiovascular events. The results, however, do 
show that the prevalence of macrovascular disease is not only associated with a high 
classical cardiovascular risk pro!le (estimated by the UKPDS risk score), but, in addition, 
is associated with an increased skin auto#uorescence. The prospective follow-up data of 
our study on cardiovascular events are required to con!rm that skin auto#uorescence 
has additive value in predicting future cardiovascular disease events on top of the 
UKPDS risk score. These data will be presented in the future.
 Our results also contribute to establish the generalizability of skin auto#uorescence 
results in patients with Type  2 diabetes concerning the association between skin 
auto#uorescence with diabetic complications. First of all, within our study, no 
di"erences in skin auto#uorescence results were found between the !ve participating 
medical centres. Also, the levels of skin auto#uorescence in these subgroups, according 
to diabetic complications, are very similar to the skin auto#uorescence levels found in 
the population with Type 2 diabetes previously described by Lutgers et al.9 Their study 
group found a skin auto#uorescence of 2.77 in a population of nearly the same age 
as our group. Without any complications, mean skin auto#uorescence was 2.57, with 
microvascular complications mean skin auto#uorescence was 2.71 and with both micro- 
and macrovascular complications mean skin auto#uorescence was 3.12. This is exactly 
the same grading of skin auto#uorescence according to diabetic complications that we 
found in the present study. Chabroux et al15 also found very high skin auto#uorescence 
values in a cohort of patients with Type 1 diabetes with a median age of 30 years and 
a diabetes duration of 17 years. Without diabetic complications, subjects had a skin 
auto#uorescence of 1.86 (which is the 93th percentile adjusted to age) and, for subjects 
with both retinopathy and nephropathy, skin auto#uorescence was 2.94 (which is the 
99.9th percentile). This study in young patients with Type 1 diabetes cannot directly be 
compared with results found in patients with Type 2 diabetes, but is does again show 
that skin auto#uorescence is elevated in patients with diabetes and even signi!cantly 




Our current results are based on cross-sectional data, which are by de!nition inferior 
to prospective data. This study has, however, been designed as a prospective follow-up 
study. Follow-up data on complications and mortality will be presented in the future.
 Macrovascular disease was de!ned as a known history of coronary disease, 
cerebrovascular disease or peripheral artery disease. We did not screen all patients for 
macrovascular disease by, for example, coronary angiogram or computed tomography 
cerebrum of ankle-arm index. Therefore, asymptomatic macrovascular disease may 
have been missed in our study.
 The used version of the AGE Reader in this study was limited by an in#uence of skin 
pigmentation. Skin re#ectance had to be above 12% for an accurate reading. This led 
to inaccurate skin auto#uorescence readings in 53 patients who therefore could not be 
included in the analysis. Development of AGE Reader is still ongoing and adjustments 
in the device have in the meantime improved the accuracy of readings in patients with 
high skin pigmentation.12
Conclusions
This study con!rms in a multi-centre secondary care setting that skin auto#uorescence 
is increased in patients with Type 2 diabetes and has a graded relation with the presence 
of micro- and macrovascular complications. In Type 2 diabetes, skin auto#uorescence 
appears to be independently associated with the presence macro- and microvascular 
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Part 1 gives an introduction to advanced glycation end products and skin auto-
#uorescence with chapter 2 focussing on their role in renal failure. Advanced glycation 
end products are formed during hyperglycemia, oxidative stress and in#ammation. A 
complex and diverse process causes glycation and oxidation of mostly proteins, but also 
lipids and DNA in the body. The end product is called advanced glycation end product 
(AGE). This process causes irreversible structural changes and deformation of proteins, 
lipids and DNA leading to malfunction. Furthermore, AGE can activate pro-in#ammatory 
receptors, especially the receptor for AGE (RAGE) with negative consequences. In tissues 
with a long lifetime, AGE continue to accumulate during life. 
 An increased accumulation of AGE is seen in diabetes mellitus (as a result of 
hyperglycemia), renal failure (as a result of oxidative stress and decreased renal 
clearance of AGE precursors) and chronic in#ammatory diseases (as a result of activation 
of in#ammatory cells). 
 The increased accumulation of AGE seen in these conditions plays a major 
pathogenetic role and leads to long-term cardiovascular complications and mortality. 
AGE contribute to an accelerated progression of atherosclerosis by several mechanisms. 
Crosslinking of vascular collagen leads to arterial sti"ness, hypertension and vessel 
leakage. Dysfunction of AGE modi!ed lipids also causes a negative cascade. AGE interact 
with their receptors on endothelial cells, smooth muscle cells and macrophages inducing 
adhesion molecules and cytokine expression. AGE can reduce the release of nitric oxide 
or captivate nitric oxide. In patients with type 2 diabetes, skin auto#uorescence (SAF) 
predicts cardiac mortality and the occurrence of micro- and macrovascular complications. 
In patients on haemodialysis, SAF is highly elevated and predicts mortality. After renal 
transplantation SAF is lower than during haemodialysis, but still remains elevated and is 
a strong risk factor for chronic renal transplant dysfunction and mortality. 
 Measuring AGE and AGE accumulation is notoriously di$cult, also because it is a 
heterogeneous group. Since 2006 AGE accumulation can be non-invasively assessed by 
the AGE reader. This method uses the #uorescent properties of some AGE. 
Part II elaborates on potential disturbing factors in the measurement of SAF. In chapter 
3 the relation between SAF and short- and intermediate term glycemic variations is 
evaluated by both original data and a review of literature. We show that acute changes 
in glucose levels during an oral glucose tolerance test, even in patients with impaired 
glucose tolerance, do not in#uence SAF. AGE rich meals result in a transient postprandial 
rise in SAF of 10% 2-4 hours later, probably caused by the AGE content of the meal. In 
type 1 diabetes mellitus major intermediate term improvements of glycemic control as 
Summary, general discussion and future perspectives
8
119
depicted by multiple HbA1c measurements were associated with lower skin AGE levels. 
In a well-controlled, stable type 2 diabetes mellitus cohort, only a weak correlation was 
found between SAF and HbA1c. In both studies, skin AGE content/SAF levels predicted 
diabetic complications with an accuracy superior to that of HbA1c. SAF also had superior 
sensitivity to either fasting glucose or HbA1c in diagnosing IGT and diabetes mellitus.
 Chapter 4 assesses the in#uence of potential disturbing factors in SAF measurement. 
Dark pigmentation of the skin is a well-documented limitation in the SAF measurement. 
Improvements in the auto#uorescence reader however have led to a an extension of 
reliable SAF measurement in darker skin to re#ectance levels of approximately 6% (up 
to Fitzpatrick skin type 5). We show that measurement of SAF is also strongly a"ected 
by several skin creams, causing a falsely increased SAF. This e"ect was often not fully 
corrected by alcohol swabs and washing with soap and may persist for many days. 
Marked hyperemia and vasoconstriction also in#uence SAF, respectively giving a 
decreased and increased measured SAF. Therefore it is strongly advisable to avoid these 
potential error sources.
Part III focuses on SAF, as an estimate of AGE accumulation, in atherosclerotic disease in 
di"erent vascular beds. In chapter 5 we present the !rst report of SAF levels in patients 
with carotid artery disease. SAF was higher in the 56 patients with carotid artery stenosis 
compared to a healthy control group (matched for age and sex), especially in the 
younger age group. Coexistence of carotid artery stenosis and peripheral artery disease 
(PAD) resulted in an even higher SAF than in patients with carotid artery stenosis only. 
Regression analysis showed that age, smoking, diabetes mellitus, renal function and 
PAD were determinants of SAF, but carotid artery stenosis was not. The results suggest 
that increased SAF can be seen as an indicator of atherosclerotic burden. 
 In chapter 6 we investigate the hypothesis that SAF is elevated in peripheral artery 
disease (PAD) as suggested by the study presented in chapter 5. A case control study was 
performed in 492 patients with PAD and 164 controls, matched for age and presence of 
diabetes mellitus. SAF was higher in patients with peripheral artery disease compared to 
controls. PAD patients with cardiovascular co-morbidity had a higher SAF as compared 
to those without, also after correction for confounders. Regression analysis showed that 
age, smoking, diabetes mellitus, chronic kidney disease and a history of cerebrovascular 
disease or AAA were independently associated with an increased SAF in the patients with 
PAD. This study proves that SAF, as a measure of tissue AGE deposition, is considerably 
increased in patients with PAD as compared to controls. This increase is independent of 
the presence of cardiovascular risk factors or other established cardiovascular disease 
although these conditions are associated with a further increase of SAF. These !ndings 
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underscore the importance of AGE in PAD, irrespective of the presence of diabetes and 
renal insu$ciency. 
 Chapter 7 presents the baseline cross-sectional data of a prospective study that aims 
to con!rm the association between SAF and diabetic complications in patients with 
type 2 diabetes in a multicenter secondary care setting. We analysed 563 subjects with 
type 2 diabetes mellitus followed in 5 Dutch hospitals. SAF was elevated compared to 
historical age-matched healthy controls. SAF levels showed a graded increase with the 
presence and severity of diabetic micro- and macrovascular complications. Regression 
analysis showed that age, duration of diabetes, serum creatinine, gender and SAF 
were independent determinants of macrovascular complications. The level of SAF was 
determined by age, smoking, serum creatinine and macrovascular complications. This 
study con!rms that SAF is increased in type 2 diabetic patients and has a graded relation 
with micro- and macrovascular complications. Also, SAF is an independent determinant 
of macrovascular complications, on top of classical risk factors. 
In summary, this thesis has two major messages. First of all, it shows several factors 
that may disturb SAF measurement and thus should be avoided. Secondly, it presents 
evidence that SAF, as a measure of AGE accumulation, is consistently elevated in 
atherosclerosis in di"erent vascular beds, irrespective of the presence of diabetes 
mellitus and renal insu$ciency. 
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DISCUSSION AND FUTURE PERSPECTIVES
The role of AGE, their accumulation in tissue and its deleterious consequences have been 
partly elucidated as depicted in Part I. However, some of the e"ects are undoubtedly still 
unknown or incompletely understood. Partly, we understand the negative consequences 
of AGE, but the body might counteract the negative consequences of AGE by protective 
mechanisms. What these protective mechanisms are and how they work largely remains 
to be elucidated. Research data suggest that an increased circulating soluble receptor 
for AGE (sRAGE) acts as a decoy receptor.1 Binding of AGE to sRAGE would facilitate 
clearance and also prevents activation of cellular receptors of AGE which would cause 
pro-in#ammatory intracellular signals.1 Genetic in#uences also may play an important 
role. In patients with rheumatic arthritis, polymorphisms of the receptor for AGE (RAGE) 
in#uence levels of sRAGE and are associated with disease activity and ischemic heart 
disease (submitted data by Hans Nienhuis). Some polymorphisms of RAGE seemed 
protective against severe rheumatic disease activity and ischemic heart disease. Similarly 
in systemic lupus an association was found between certain RAGE polymorphisms and 
disease severity in lupus nephritis.2 However, no association of RAGE gene polymorphisms 
with type 2 diabetes mellitus, diabetic retinopathy and nephropathy was found by 
Kang et al.3 Theoretically, protective mechanisms that inhibit AGE formation in the !rst 
place may also exist. Up-regulation or increased expression of antioxidant mechanisms 
may be triggered by increased serum AGE. The enzyme glyoxalase 1 (GLO1) is a known 
defence mechanism against the formation of AGE out of methylglyoxal/glyoxal. GLO1 
breaks down methylglyoxal and glyoxal, thereby detoxifying these precursors of AGE. 
Polymorphisms in the GLO1 gene were, however, not associated with the prevalence of 
hypertension, markers of atherosclerosis, renal function and AGE. These polymorphisms 
are only weakly associated with pulse pressure and systolic blood pressure in two Dutch 
cohorts of patients with normal glucose metabolism, impaired glucose metabolism and 
type 2 diabetes mellitus.4
 Cells with large accumulation of AGE may trigger a self-destructing mechanism 
like apoptosis, as suggested by some researchers.5,6 Weather epigenetic changes are of 
in#uence and weather AGE maybe directly induce epigenetic changes has yet to be 
explored. Hopefully, future research will give more insight into such mechanisms.
 What is the best method to determine AGE accumulation in tissue? Often, the 
speci!c AGE content in skin biopsy is regarded as the golden standard. However, this 
method has several #aws as a golden standard. First of all, determination of a single 
speci!c AGE  is not representative for the whole spectrum of AGE. Measurement of 
several speci!c AGE in tissue gives a better estimate, but still represents only a selection 
of known AGE. Also, when measuring several AGE, how to weigh the di"erent AGE? 
Chapter 8
122
Therefore, there are limitations to tissue AGE content as a golden standard for AGE 
accumulation in tissue. The need for skin biopsies and for elaborate and expensive 
laboratory assays also makes wide use in medical practice impossible. Measurement of 
skin auto#uorescence with the AGE Reader is a much easier and non-invasive method 
to estimate AGE accumulation in tissue.7 As explained in the introduction of this theses, 
multiple validation studies have shown convincingly and consistently that SAF has a 
strong correlation with both #uorescent and even non #uorescent AGE content in skin 
biopsies. Skin AGE content explained the major part of the variance (up to 76%) in the 
SAF signal in a pooled analysis of three validation studies.8,7 Skin auto#uorescence can 
therefore be used as an indirect, noninvasive estimate of AGE accumulation in tissue.7 
Still, there are pitfalls: the #uorescent properties detected by the AGE reader are not 
speci!c for AGE. NADPH has the same auto#uorescent properties and, therefore, may 
confound the estimation of AGE by auto#uorescence. Haemoglobin and melanin 
absorb the UVA light of the AGE reader, possibly interfering with measurement. 
Bilirubin also absorbs UVA light and, therefore, hyperbilirubinaemia may also interfere 
with SAF measurements. With all these limitations, SAF still is a predictor of mortality 
and complications in diabetes and renal failure.9-12 In conclusion, there remain many 
di$culties and obstacles in reliably measuring tissue accumulation of AGE, but so far 
skin auto#uorescence is the most practical and patient-friendly method available. 
Part II shows that several precautions need to be taken to ensure a reliable SAF 
measurement. Use of skin creams on the volar forearm in the 2 weeks before SAF 
measurement should be avoided. Extreme dermal hyperaemia or vasoconstriction on 
the measuring site must be avoided. As a 10 % rise of SAF measurements can be seen 2-4 
hours post oral exposure to a large AGE load we recommend a fasting measurement to 
improve accuracy. In previously performed studies these precautions were insu$ciently 
taken into account. Even so, these studies showed a predictive value for mortality, 
microvascular and macrovascular complications.10-13 Predictive results of the AGE reader 
can only improve when these precautions are conscientiously taken. The need for these 
(easily taken) measures does not negatively a"ect the possibilities of the AGE Reader 
for a broad application in the future. For blood pressure measurements, similarly, 
standardized conditions are taken into account to avoid large #uctuation of values.
 The AGE reader is also still in further development, and continuing software 
improvements may also lead to increasing reliability of SAF measurement. For example, 
error detection for external light, and automatic warnings by the system for probable 
unreliable measurements due to use of skin creams, skin tanners and sunscreen 
blockers (as identi!ed by algorithms using SAF and skin re#ectance levels) will soon be 
implemented. 
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Part III presents proof that SAF, as an indirect estimate of AGE accumulation, is elevated 
in atherosclerotic disease in di"erent vascular beds. Chapter 7 shows that SAF is an 
independent determinant of macrovascular complications in patients with type 2 
diabetes, on top of classical risk factors. Chapter 5 describes that SAF levels are increased in 
patients with carotid artery disease and peripheral artery disease, irrespective of diabetes 
or renal failure. In chapter 6 we show that SAF is elevated in patients with peripheral 
artery disease. Also, SAF increased even further with cardiovascular co-morbidity (AAA 
or CVA), indicating that SAF may be seen as a cumulative score of atherosclerotic burden. 
These !ndings underscore the importance of AGE in atherosclerotic disease, irrespective 
of the presence of diabetes and renal insu$ciency. Moreover, as SAF increases further 
with Also, earlier studies showed that a high SAF predicted cardiovascular mortality in 
patients with type 2 diabetes and in patients on haemodialysis.10,13 SAF also proved to 
be elevated in chronic in#ammatory diseases like rheumatoid arthritis, systemic lupus 
erythematosis and granulomatosis with polyangiitis.14-16 Interestingly, these diseases 
are also characterized by a high risk of premature atherosclerotic events. A relation was 
found between small artery elasticity and SAF in patients with SLE, again suggesting the 
role of AGE accumulation in atherosclerosis.17 A logical conclusion: SAF appears to be a 
marker of vascular damage. AGE accumulation is however non-speci!c for any disease: 
glycemic stress and oxidative/carbonyl stress can result from a wide range of diseases 
and medical situations.  
 Some acute diseases can also temporary cause elevated levels of SAF, like sepsis and 
acute myocardial infarction.18,19 This temporarily elevation of SAF is probably caused by 
high oxidative stress and high serum AGE, but possibly not by accumulation of AGE in 
tissue. This contrasts with chronic diseases where an increased SAF indicates high tissue 
AGE and appears to re#ect atherosclerotic burden. 
 Maybe the spectrum of diseases that exhibit an elevated  SAF with broaden in 
future years. Theoretically one could think of chronic diseases like Morbus Crohn, 
colitis ulcerosa, COPD, psoriasis or severe eczema, because of the chronic generalized 
in#ammation. Another group of patients that have endured a great amount of oxidative 
stress are survivors of cancer who had long-term chemotherapy. Young patients who 
survive Hodgkin’s disease are known to have a high risk of future coronary events. It 
is thought that this is the result of chemical damage of chemotherapy and radiation 
to the arterial vessel wall. However, maybe AGE accumulation plays an important role. 
Furthermore, AGE accumulation in DNA or transcription factors could theoretically be 
a direct cause of cancer. It would be interesting to study SAF levels in these groups of 
patients. Even so, it may well be that out of all long lived tissues that can be damaged by 
AGE, the vascular wall endures most damage and causes most morbidity and mortality 
due to continuous exposure to (external) factors transported in the blood stream. In that 
Chapter 8
124
case, all chronic diseases that result in an increased AGE accumulation would probably 
also exhibit premature vascular events.
 Normally, cardiovascular risk is estimated by the classical risk factors: age, blood 
pressure, lipid pro!le, smoking behaviour and diabetes mellitus. However, evidence 
is growing that SAF adds information on top of the classical risk factors in predicting 
cardiovascular events. In patients with diabetes mellitus type 2 SAF added information 
in predicting cardiovascular mortality on top of the UKPDS risk score.11 Cardiovascular 
risk in in#ammatory diseases like rheumatoid arthritis, SLE and GPA cannot be explained 
by the classical risk factors, while increased SAF is associated with increased vascular 
damage in these groups of patients.20 Prospective follow-up studies need to further 
determine the value of SAF as predictor of cardiovascular events in di"erent groups 
of patients (other than diabetes mellitus or renal failure). Such a study is now being 
executed in a large cohort of patients with peripheral artery disease. 
 Another question that may be answered by future research is whether consecutive 
SAF measurements can be used in follow-up. For example, can a repeated SAF 
measurement after 5-10 years be used to monitor e"ect of therapy or progression 
of atherosclerotic disease? Theoretically, a repeated measurement within 5 years 
may not be useful, because AGE accumulation in tissue is a slow process over many 
years. However, quite recently, Arsov et al showed in an extreme model of increased 
AGE accumulation in patients on haemodialysis, that the 1-years change in SAF was a 
stronger predictor of mortality than the baseline SAF (Arsov, Arti!c Organs, in press). 
 The next issue to be solved is what to do after determining that there is increased 
AGE accumulation. Maybe patients with a high SAF may bene!t from more aggressive 
treatment of classical risk factors (i.e. lower LDL-cholesterol and blood pressure targets), 
similar to patients with diabetes mellitus or renal insu$ciency. It is now well accepted 
that cardiovascular risk reduction may be achieved by interventions not necessarily 
focused on the abnormal risk predictor itself. For example in diabetic or hypertensive 
persons lipid lowering is e"ective in cardiovascular risk reduction, even when lipid 
levels are not elevated. This should be subject to an intervention study. Furthermore, 
inhibition of AGE formation, breakdown of AGE-crosslinks, blocking the receptor for AGE 
may become treatment targets in cardiovascular disease. The AGE formation inhibitor 
benfotiamine and the presumed crosslink breaker alagebrium have been tested, but 
provided mixed results. In diabetic nephropathy, benfotiamine reversed increased 
urinary albumin excretion in patients with type 2 diabetes and microalbuminuria in 
some studies, but failed to do so in another study.21,22 Alagebrium had a positive e"ect 
of isolated systolic hypertension in one study,23 while no e"ect was seen in on systolic 
of diastolic function or exercise tolerance in heart failure.24 The latter study was of 
relatively short duration (36 weeks), which may explain the negative results. Soluble 
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RAGE analogues are also under development to scavenge circulating AGE. So far none 
of these drugs have yet been introduced for clinical use because of mixed results on 
e$cacy and safety concerns. Interestingly, drugs that are currently prescribed to treat 
diabetes mellitus, hypertension and hypercholesterolemia may have e"ects on AGE. For 
example, Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor 
blockers (ARB) have been shown to reduce the formation of AGE and a"ect the receptor 
for AGE.25-28 Also, ACE inhibitors appear to upregulate the soluble receptor for AGE.26 
Statins also have also been shown to reduce the receptor for AGE as well as serum levels 
of AGE which may explain their known pleiotrophic e"ects.29-33 Reducing the intake of 
AGE in food and smoke also is a possible target to lower AGE accumulation. A diet low in 
AGE is unpalatable, however. 
 
Concluding, there is a lot of work yet to be done in the !eld of AGE accumulation and 
SAF. It makes me very humble about the data I present in this thesis. Socrates expressed 
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Deel 1 geeft een overzicht over de rol van advanced glycation end products (AGE), 
waarbij in hoofdstuk 2 de nadruk ligt op hun rol bij nierfalen. AGE ontstaan als gevolg 
van versuikering en/of oxidatie van eiwitten, vetten en DNA. AGE ontstaan in feite bij 
alle mensen als onderdeel van het normale verouderingsproces. Ze geven schade 
aan weefsels doordat ze onomkeerbare verbindingen aangaan met allerlei eiwitten 
die daardoor misvormd raken en niet goed kunnen functioneren. Ze kunnen ook 
verbindingen vormen tussen eiwitten, bijvoorbeeld in het bindweefsel van de vaatwand, 
die daardoor zijn elasticiteit verliest. Verder activeren AGE een speci!eke celmembraan 
receptor (RAGE genoemd) die binnen de cel tot allerlei negatieve processen leidt. Als 
AGE ontstaan in weefsel met een korte levensduur, wordt de AGE vanzelf afgebroken, 
zodat de schade die de AGE kan aanrichten beperkt is. Dit is anders bij AGE die ontstaan 
in eiwitten of weefsels die 15 tot 20 jaar of zelfs levenslang meegaan. Bindweefsel in de 
huid en vaatwand hebben bijvoorbeeld een levensduur van 10-20 jaar. Opstapeling van 
AGE in weefsels met een lange levensduur treedt in verhoogde en versnelde mate op 
bij patiënten met diabetes, chronisch nierfalen en chronische ontstekingsziekten (bv 
reumatoïde artritis). Bij diabeten leidt de hoge suikerspiegel in het bloed tot verhoogde 
versuikering van eiwitten en dus een verhoogde AGE stapeling. Bij nierfalen leidt het 
slechter uitscheiden van voorlopers van AGE tot een stapeling van deze schadelijke 
sto"en. Bij ontstekingsziekten als reumatoïde artritis veroorzaken schadelijke sto"en van 
de ontstekingscellen voor versnelde AGE vorming. Dit verklaart waarom deze patiënten 
groepen een hoog risico op allerlei chronische complicaties hebben en vroegtijdig 
overlijden. Eigenlijk kan AGE opstapeling in weefsels met een lange levensduur gezien 
worden als eindorgaanschade, een metabool geheugen van schade door oxidatie en 
versuikering. 
Hoe kan deze kennis gebruikt worden in de praktijk? Hoe kun je AGE stapeling 
meten? Het betreft namelijk een verzameling van schadelijke eindproducten, niet 
één speci!eke stof. Speci!eke AGE met een bekende structuur kunnen met speciale 
methoden gemeten worden in bloed. Dit geeft echter een momentopname van de 
hoeveelheid AGE in bloed, terwijl we geïnteresseerd zijn in de hoeveelheid stapeling 
van AGE in weefsel. Een mogelijkheid om weefsel stapeling te meten is door een 
huidbiopt te nemen en daarin de hoeveelheid van een AGE bepalen. Het nemen van een 
huidbiopt maakt routine gebruik in de praktijk echter onmogelijk. Sinds 2006 is er een 
niet belastende en eenvoudige methode beschikbaar om een schatting te maken van 
AGE stapeling in de huid: de Auto#uorescentie Reader. Dit apparaat maakt gebruik van 
het fenomeen “auto#uorescentie”. Dit houdt in dat bij een belichting met UVA stralen 
deze AGE een andere, herkenbare lichtfrequentie uitstralen. Met de Auto#uorescentie 
Reader wordt een meting gedaan op de onderarm door belichting met UVA stralen. 
Samenvatting in het Nederlands (Dutch summary)
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Een spectrometer analyseert vervolgens de herkenbare lichtfrequentie die de AGE 
terugsturen (gol#engte 420-600 nm) en het weerkaatste UVA licht. Aan de verhouding 
hiertussen wordt de auto#uorescentie berekend. Uit meerdere validatiestudies blijkt 
dat deze auto#uorescentie (SAF) een goede schatting geeft van de hoeveelheid AGE 
stapeling in de huid. SAF blijkt bij diabetes patiënten verhoogd te zijn en ook een 
voorspellende waarde te hebben voor vroegtijdig overlijden en het optreden van 
microvasculaire complicaties (langetermijns schade aan kleine bloedvaatjes zoals 
oogschade, nierschade en zenuwschade) en macrovasculaire complicaties (ader-
verkalking van grote bloedvaten waardoor hartinfarct, beroerte of vernauwde slagaders 
naar de benen). Bij hemodialyse patiënten is de SAF erg verhoogd en voorspelt het 
overlijdensrisico. Na een niertransplantatie daalt de SAF enigszins maar blijft toch fors 
verhoogd ten opzichte van normaal. Een hoge SAF is een sterke risicofactor voor het 
falen van het niertransplantaat. 
Deel II onderzoekt meerdere factoren die de SAF meting kunnen verstoren. In hoofdstuk 
3 wordt de relatie besproken tussen SAF en korte termijns en middellange termijns 
variaties in glucose waarden. Korte termijns variaties in glucose, uitgelokt door een 
gestandaardiseerde suiker belasting test (OGTT) bleken geen invloed te hebben op de 
gemeten SAF, zelfs bij neiging tot diabetes. Maaltijden die veel AGE bevatten gaven een 
tijdelijke stijging van de SAF van 10% 2 tot 4 uur na de maaltijd. In een studie bij type 
1 diabeten resulteerden drastische verbetering van glucose regulatie op middellange 
termijn (meerdere opeenvolgende HbA1c waarden) in een lagere AGE hoeveelheid 
in huidbiopten. In een cohort van goed ingestelde type 2 diabeten werd slechts een 
zeer zwakke relatie gevonden tussen SAF en HbA1c. In beide studies voorspelde de 
hoeveelheid AGE in de huid (gemeten via huid biopten dan wel SAF) het risico op 
toekomstige micro- en macrovasculaire complicaties beter dan het HbA1c. Verder heeft 
SAF een hogere sensitiviteit dan nuchter glucose of HbA1c om beginnende diabetes te 
diagnosticeren. 
 Hoofdstuk 4 bespreekt welke factoren van de huid de SAF meting kunnen verstoren. 
Een donker gepigmenteerde huid maakt een SAF meting moeizaam. Door recente 
verbeteringen in de auto#uorescentie reader wordt de meting ook bij een donkere 
huidpigmentatie steeds betrouwbaarder. Wij toonden aan dat vele huid crèmes 
(met name dagcrème, zonnebrandcrème en zelf-bruinende crème) en extremen 
in doorbloeding van de huid de SAF waarde sterk beïnvloeden. Deze verstorende 
factoren moeten vermeden worden om een betrouwbare SAF meting te waarborgen. 
Vochtigheid van de huid beïnvloedde de SAF meting niet.
Chapter 9
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In deel III staat centraal dat AGE stapeling een grote rol lijkt te hebben in verschillende 
uitingen van aderverkalking (atherosclerose)
 Hoofdstuk 5 laat zien dat SAF, als schatting van de AGE ophoping in de huid, 
verhoogd is bij patiënten met carotis stenose (vernauwing van een halsslagader) en 
perifeer vaatlijden (vernauwing van vaten naar de benen). SAF was fors hoger bij de 
56 patiënten met carotis stenose vergeleken met de gezonde controle groep, vooral 
in de jongere leeftijdsgroep. Patiënten met zowel carotis stenose én perifeer vaatlijden 
hadden weer een hogere SAF dan patiënten met alleen carotis stenose. Bij regressie 
analyse bleek de SAF met name bepaald door leeftijd, roken, diabetes, nierfalen en 
perifeer vaatlijden. Deze resultaten suggereren dat SAF gezien kan worden als een maat 
voor uitgebreide atherosclerose. 
 In hoofdstuk 6 onderzoeken we de hypothese dat SAF ook verhoogd is bij perifeer 
vaatlijden (PAD). In een case control studie van 492 patiënten met PAD en 164 controle 
mensen, gematched op leeftijd en diabetes, bleek SAF inderdaad verhoogd ten opzichte 
van de controle groep. Bij de patiënten met PAD werd een verdere stijging van de SAF 
gezien indien er ook sprake was van een doorgemaakte beroerte (CVA) of een verwijde 
buikslagader (aneurysma). Regressie analyse toonde dat leeftijd, roken, diabetes, 
chronisch nierfalen en een doorgemaakt CVA of AAA onafhankelijke samenhingen met 
een verhoogde SAF bij depatiënten met PAD. Deze studie bewijst dat SAF fors verhoogd 
is bij patiënten met perifeer vaatlijden ten opzichte van controle patiënten zonder 
vaat-lijden, onafhankelijk van de traditionele risicofactoren voor hart- en vaatziekten. 
Hoe meer aanvullend vaatlijden naast het perifeer vaatlijden, hoe verder de SAF stijgt. 
Deze bevindingen bevestigen dat AGE een grote rol lijken te spelen in atherosclerose, 
losstaand van diabetes of nierfalen. 
 Hoofdstuk 7 presenteert de aanvangsdata van een in opzet prospectieve studie. We 
analyseerden 563 patiënten met type 2 diabetes die behandeld werden in 5 verschillende 
ziekenhuizen. SAF was fors verhoogd bij de diabetes patiënten ten opzichte van gezonde 
controle mensen. Met toename en ernst van de micro- en macrovasculaire complicaties 
verhoogde de SAF ook stapsgewijs. Bij regressie analyse bleek SAF een onafhankelijke 
determinant voor macrovasculaire complicaties. De studie bevestigt dat SAF verhoogd 
is bij patiënten met diabetes type 2 en dat er een sterke relatie bestaat tussen SAF en 
diabetische complicaties. 
 Kortom, dit proefschrift heeft 2 belangrijke conclusies. Allereerst zijn er meerdere 
factoren die de SAF meting beïnvloeden. Deze storende factoren moeten vermeden 
worden om een betrouwbare meting te waarborgen. Ten tweede spelen AGE een 
grote rol in het ziekteproces van aderverkalking. SAF, als maat voor AGE stapeling, is 
consequent verhoogd bij meerdere uitingen van atherosclerose. 
DISCLAIMER
The articles presented in this thesis may have minor textual di"erences with the 
published version in the medical journals. Besides these incidental di"erences in 





Het afronden van dit proefschrift is een gedenkwaardig moment voor mij. Hierbij kijk ik 
met dankbaarheid terug op de hulp die ik van vele mensen ontving in het bereiken van 
dit doel. Een aantal mensen verdienen speci!ek een woord van dank.
Mijn (co)promotoren Prof dr. R.O.B. Gans, Prof. dr. A.J. Smit en Dr. J.D. Lefrandt wil ik 
speciaal bedanken voor hun bijdrage.
Allereerst grote dank aan Dr. J.D Lefrandt. Tijdens het hele traject heb ik van hem 
veel steun, positieve stimulans en inzet ontvangen. Beste Joop, je bent altijd blijven 
meedenken over het beloop van mijn promotietraject en kwam hierbij meerdere 
malen met geniale ideeën aanzetten. Ook dank voor je hulp bij het maken van !guren 
in gra!sche programma’s waar ik (als Nederlandse) toch echt geen kaas van gegeten 
had. Joop, jij was echt onmisbaar. Door jou bleef ik het enthousiasme en de motivatie 
houden om door te gaan met het promotieonderzoek, ondanks dat dit naast de baan 
als internist in Heerenveen lastig was. 
Andries, jouw rustige en prettige manier van begeleiden heb ik zeer gewaardeerd. 
Je hebt me met raad en daad terzijde gestaan met allerlei praktische en inhoudelijke 
vraagstukken. Hierbij was je altijd laagdrempelig te benaderen. Ondanks jouw grote 
staat van dienst en je scherpe en nuchtere visie ben je altijd bescheiden qua instelling 
gebleven. Wat mooi dat je inmiddels benoemd bent tot bijzonder hoogleraar in de 
Vasculaire Geneeskunde. Een titel die je zeker verdient.
Beste Rijk, jouw steun en vertrouwen in mij waren erg belangrijk voor mij. Dit des 
te meer omdat ik grote bewondering heb voor je grote gedrevenheid als medicus 
en wetenschapper. Eén opmerking zal ik nooit vergeten. Je zei: “als jij jouw tanden 
ergens in zet, dan laat je niet meer los tot het klaar is, dus het komt goed met dat 
promotieonderzoek. Je bent wat dat betreft gewoon een tijger.” Dat compliment heeft 
mij ook geholpen om dit ook waar te maken. Toen een collega internist uit Heerenveen 
plotseling ziek werd en uitviel, werd de werkdruk in Heerenveen abrupt groter en moest 
ik meer werken om in de crisissituatie te helpen. Rijk, !jn dat jij die situatie begreep en 
toestond dat ik ten koste van mijn promotieonderzoek meer ging werken in Heerenveen. 
Een gentlemen’s agreement waar mijn collega’s in Heerenveen je dankbaar voor waren. 
Prof.dr. Zeebregts, beste Clark, mijn dank voor jouw begeleiding en hulp bij het carotis 
artikel. Ik heb bewondering voor je snelle reacties en daadkrachtige optreden in het 
maken én submitten van de artikelen. Dit zelfs tijdens vakanties en weekenden, waarbij 
ik me zelfs een reactie herinner vanaf het vliegveld. 
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Tijdens de onderzoeken was samenwerking met meerdere personen essentieel. In het 
AURORA onderzoek is nauw samengewerkt met Peter Oomen uit het MCL Leeuwarden, 
Manuel CastroCabezas uit het Sint Franciscus Gasthuis te Rotterdam, Jan Jager uit 
het Diakonessenhuis Meppel en Teri Brouwer uit het Onze Lieve Vrouwe Gasthuis te 
Amsterdam. In het OLVG heb ik goede hulp gekregen van Lucy Schrijnders en Rosa 
Regez en in het SFG van mevrouw Ferwer. Het artikel “External factors in#uencing skin 
auto#uorescence” heeft tot stand kunnen komen door samenwerking met Reindert 
Graa" en Marten Koetsier. Verder is hulp van de !rma DiagnOptics van grote waarde 
geweest. Dank voor jullie medewerking!
In de werkkamer in het UMCG, initieel bij de arts-assistenten interne geneeskunde 
en later aan de andere kant van het schot bij de onderzoekers van de longziekten/
reumatologie heb ik mooie tijden beleefd. Marjan, Sake, Udo: ik heb jullie zeer 
gewaardeerd als collegae-fellows vasculaire geneeskunde. Samen hebben we een 
bijzondere tijd doorgebracht. Helen, bedankt voor je medewerking aan het carotis-
artikel. Udo, aan jou speci!ek nog dank voor jouw hulp bij mijn laatste artikelen. Je 
hebt het hart van een rasechte wetenschapper en academicus! Ruth, Susanne, Maartje, 
Eef, Gerald, het was gezellig op de onderzoekskamer en soms zelfs té gezellig! Dank 
voor een luisterend oor, begrip bij onderzoeksfrustraties en hulp bij allerlei statistiek 
probleempjes. 
Ook grote waardering voor de leescommisie, die de lastige taak had om dit manuscript 
door te nemen en te beoordelen. 
Uiteraard ook mijn oprechte dank aan alle proefpersonen die meededen aan mijn 
studies. Hierbij hebben meerdere collegae ook belangeloos meegewerkt en hun 
rechterarm ter beschikking gesteld voor metingen met de AGE Reader om de invloed 
van meerdere smeersels te onderzoeken. 
Mijn !jne collega internisten uit ziekenhuis “Tjongerschans” Heerenveen wil ik laten 
weten dat ik de werksfeer, samenwerking en collegialiteit erg waardeer. Ook zij hebben 
altijd zeer positief gestaan ten opzichte van mijn promotietraject en gaven mij hiervoor 
de ruimte. Dit maakte het afronden van mijn promotieonderzoek terwijl ik al te 
Heerenveen als internist-vasculair geneeskundige werkte mogelijk. 
Mijn paranimfen Annemieke Gras-Siero en Alice Mol ben ik dankbaar dat ze mij in het 
uur der waarheid terzijde wilden staan. Jullie zijn van grote waarde voor mij! Wat !jn dat 
we zulke bijzondere momenten met elkaar mogen delen.
Dankwoord
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Verder lof voor het geduld en het begrip van mijn lieve vrienden, hechte familie en 
dierbare man. De tijd en energie die ik in het promotieonderzoek moest steken, werd 
altijd begrepen, ook als dit ten koste ging van tijd met hun. Zij zijn altijd achter mij 
blijven staan! Paps en mams, wat ik ben geworden is dankzij jullie liefdevolle opvoeding 
waarbij jullie me altijd met raad en daad terzijde stonden. Richard, ik hou enorm veel 




De auteur van dit proefschrift werd geboren op 25 januari 1977 in Ermelo. Zij volgde 
het atheneum op het Christelijk College “Groevenbeek” te Ermelo en behaalde in 1995 
haar VWO diploma. Direct aanvolgend startte zij met de studie Geneeskunde aan de 
Universiteit Utrecht. Initieel volgde zij daarnaast ook enkele vakken Natuurkunde, onder 
andere fysica van de mens en relativiteitstheorie. Tijdens haar studie Geneeskunde 
ontstond interesse voor bijzondere casuïstiek en onderzoek wat resulteerde in enkele 
bescheiden publicaties. Alvorens in 2000 door te gaan met haar coschappen besteedde 
Marjon een jaar als bestuurslid van het Utrechtsch Studenten Concert waar zij al jaren 
met passie musiceerde als hoboïste. In 2002 behaalde zij haar doctoraal examen als 
arts. Vervolgens startte zij in 2003 haar opleiding tot internist met Prof. Dr. R.O.B. Gans 
als opleider. Ze deed in het MCL Leeuwarden en het Deventer Ziekenhuis ervaring op in 
de algemene interne geneeskunde. Wederom publiceerde ze enkele case-reports naar 
aanleiding van opvallende ziektegeschiedenissen. In november 2007 startte zij met de 
specialisatie Vasculaire Geneeskunde in het Universitair Medisch Centrum Groningen 
onder leiding van Dr. A.J. Smit (inmiddels benoemd tot bijzonder hoogleraar Vasculaire 
Geneeskunde). Tijdens deze specialisatie begon zij aan het promotietraject. November 
2009 ontving ze de artsenbul. Per januari 2010 startte zij als jonge, enthousiaste internist 
in ziekenhuis “Tjongerschans” te Heerenveen waar zij een Vaatrisicopoli opzette. Per 
april 2011 is zij toegetreden tot de maatschap Interne Geneeskunde aldaar. Deelname 
aan het stafbestuur van ziekenhuis “Tjongerschans” volgde in april 2012. Die maand was 
vooral om een andere reden ook erg bijzonder: ze trouwde op 21 april met Richard Dam. 
Naast deze life-events bleef zij gestaag doorwerken aan haar promotieonderzoek die zij 
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